Dirk Schadendorf
#84,024
Most Influential Person Now
Dermatologist
Dirk Schadendorf's AcademicInfluence.com Rankings
Dirk Schadendorfmedical Degrees
Medical
#803
World Rank
#1053
Historical Rank
Dermatology
#8
World Rank
#11
Historical Rank

Dirk Schadendorfphilosophy Degrees
Philosophy
#2994
World Rank
#4938
Historical Rank
Logic
#895
World Rank
#1461
Historical Rank

Download Badge
Medical Philosophy
Dirk Schadendorf's Degrees
- Doctorate Medicine University of Cologne
- PhD Dermatology University of Cologne
Why Is Dirk Schadendorf Influential?
(Suggest an Edit or Addition)Dirk Schadendorf's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation. (2011) (5546)
- Nivolumab in previously untreated melanoma without BRAF mutation. (2015) (4628)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
- Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells (1998) (3018)
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) (2731)
- A Landscape of Driver Mutations in Melanoma (2012) (2244)
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade (2016) (2221)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) (2115)
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma (2015) (2032)
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) (1781)
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (2015) (1773)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Improved survival with MEK inhibition in BRAF-mutated melanoma. (2012) (1601)
- TERT Promoter Mutations in Familial and Sporadic Melanoma (2013) (1539)
- Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014) (1496)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. (2015) (1348)
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012) (1230)
- Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. (2000) (1187)
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018) (1137)
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial (2015) (1097)
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. (2010) (1068)
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma (2017) (964)
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (889)
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. (2018) (874)
- Melanoma (2018) (873)
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. (2012) (819)
- Highly Recurrent TERT Promoter Mutations in Human Melanoma (818)
- PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma (2018) (807)
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
- Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. (2014) (792)
- The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. (2014) (769)
- Melanoma genome sequencing reveals frequent PREX2 mutations (2012) (695)
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) (692)
- MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. (2013) (578)
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. (2018) (577)
- Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. (2009) (541)
- Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. (2016) (528)
- Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. (2006) (523)
- Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma (2014) (519)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. (2016) (467)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2017) (462)
- Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. (2006) (457)
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab (2016) (449)
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab (2016) (442)
- IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. (1993) (440)
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network (2013) (411)
- Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. (2013) (381)
- Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. (2018) (377)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (376)
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. (2018) (372)
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. (2017) (344)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
- NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. (2009) (328)
- A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. (2013) (316)
- Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model (2011) (314)
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. (2017) (312)
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. (2017) (308)
- Human mast cells produce IL-8. (1993) (307)
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. (2022) (301)
- RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. (2012) (298)
- Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. (2017) (295)
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab (2015) (285)
- TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism (2013) (279)
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (276)
- Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma” (2013) (275)
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. (2016) (270)
- Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task. (2019) (257)
- sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (251)
- Lack of clinical efficacy of imatinib in metastatic melanoma (2005) (246)
- Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review (2018) (242)
- Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. (2012) (241)
- Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. (2015) (240)
- Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging (2015) (240)
- Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. (2004) (231)
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. (2017) (229)
- Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial (2019) (224)
- Metabolic heterogeneity confers differences in melanoma metastatic potential (2019) (222)
- Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. (2012) (219)
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo (2020) (212)
- Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth (2012) (212)
- Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. (2020) (212)
- Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). (2011) (210)
- TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. (2014) (207)
- Immunotherapy in melanoma: Recent advances and future directions. (2017) (206)
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. (2016) (200)
- Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma (2015) (199)
- Analysis of dermatologic events in vemurafenib-treated patients with melanoma. (2013) (199)
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells (2013) (198)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations (2018) (196)
- Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma (2015) (191)
- Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma (2009) (189)
- Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study (2016) (188)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. (1997) (187)
- Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. (2012) (185)
- Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. (2015) (183)
- A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task. (2019) (183)
- Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial (2019) (181)
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma (2018) (176)
- Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas (2013) (175)
- Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B (2009) (174)
- Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study (1998) (174)
- Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. (2012) (172)
- Drug‐resistance in human melanoma (2001) (172)
- Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. (2014) (171)
- Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. (2009) (171)
- Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey (2011) (170)
- Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials (2015) (169)
- Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. (2005) (167)
- Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. (2010) (166)
- Superior skin cancer classification by the combination of human and artificial intelligence. (2019) (165)
- Primary staging and follow-up in melanoma patients – monocenter evaluation of methods, costs and patient survival (2002) (165)
- Superior skin cancer classification by the combination of human and artificial intelligence. (2019) (165)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (162)
- Melanocytes as "sensory" and regulatory cells in the epidermis. (1993) (160)
- Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions (2017) (157)
- Serological detection of cutaneous T-cell lymphoma-associated antigens. (2001) (157)
- Deep neural networks are superior to dermatologists in melanoma image classification. (2019) (156)
- The validity of circulating microRNAs in oncology: Five years of challenges and contradictions (2014) (156)
- Increased expression of epidermal fatty acid binding protein, cofilin, and 14‐3‐3‐σ (stratifin) detected by two‐dimensional gel electrophoresis, mass spectrometry and microsequencing of drug‐resistant human adenocarcinoma of the pancreas (1999) (155)
- Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety (2014) (155)
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2021) (153)
- Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. (2013) (153)
- The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice (1999) (152)
- Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. (2014) (149)
- Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. (2018) (148)
- Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images. (2019) (148)
- Survival of patients with advanced metastatic melanoma: The impact of novel therapies. (2016) (146)
- Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. (2005) (146)
- Endosialin (Tem1) is a marker of tumor-associated myofibroblasts and tumor vessel-associated mural cells. (2008) (145)
- Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. (2013) (145)
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control (2013) (145)
- Genetic and morphologic features for melanoma classification (2010) (144)
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. (2020) (143)
- The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling (2014) (142)
- Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. (2017) (141)
- miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes. (2013) (137)
- Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma (2011) (136)
- Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma (2000) (134)
- Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. (2017) (132)
- Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. (2017) (131)
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma (2010) (131)
- Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 (2002) (129)
- Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. (2002) (129)
- Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab (2016) (128)
- Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. (2007) (128)
- Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. (2017) (127)
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial (2020) (126)
- Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. (2005) (126)
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases (2013) (125)
- B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis (2007) (124)
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (124)
- Pathologist-level classification of histopathological melanoma images with deep neural networks. (2019) (124)
- Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials (2017) (124)
- Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. (2012) (123)
- Vemurafenib Potently Induces Endoplasmic Reticulum Stress–Mediated Apoptosis in BRAFV600E Melanoma Cells (2013) (123)
- Vemurafenib reverses immunosuppression by myeloid derived suppressor cells (2013) (123)
- Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression (2014) (123)
- Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. (2012) (120)
- Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. (2019) (119)
- Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. (2003) (119)
- Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks. (2019) (119)
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) (119)
- Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. (2010) (119)
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial (2020) (116)
- Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours (1993) (114)
- The role of the proteasome activator PA28 in MHC class I antigen processing. (2002) (114)
- Predictors of Sun Protection Behaviors and Severe Sunburn in an International Online Study (2010) (113)
- Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo (1996) (113)
- Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up (2013) (112)
- Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. (2005) (112)
- MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. (2017) (111)
- Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC) (2017) (111)
- Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two‐dimensional electrophoresis (2000) (110)
- Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. (2020) (110)
- Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation (1995) (109)
- Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. (1995) (108)
- Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. (2009) (108)
- Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. (1998) (107)
- PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells. (2010) (107)
- Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial (2017) (107)
- Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. (2002) (106)
- Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. (2009) (105)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. (2021) (104)
- LBA18Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations (2017) (103)
- A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma (2011) (102)
- In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group (2006) (102)
- TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours (2013) (101)
- Complete loss of HLA class I antigen expression on melanoma cells: A result of successive mutational events (2003) (100)
- Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (2015) (100)
- DFNA5 (ICERE‐1) contributes to acquired etoposide resistance in melanoma cells (2001) (100)
- TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas (2014) (99)
- Short German guidelines: Malignant melanoma (2008) (99)
- An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma (2008) (98)
- Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade (2018) (97)
- Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. (1998) (95)
- Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma. (2013) (95)
- Somatic alterations in the melanoma genome: A high‐resolution array‐based comparative genomic hybridization study (2010) (94)
- Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. (2016) (93)
- Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. (2009) (93)
- Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. (2008) (92)
- Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions* (2001) (91)
- Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene mgmt (2001) (91)
- Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. (1998) (90)
- A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (90)
- Functional HLA‐DM on the surface of B cells and immature dendritic cells (2000) (90)
- Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. (2008) (89)
- Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. (2012) (88)
- Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. (2018) (88)
- Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). (2021) (88)
- Small molecules and targeted therapies in distant metastatic disease (2009) (88)
- Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells (2009) (87)
- Genome-wide association meta-analyses combining multiple risk phenotypes provides insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (87)
- Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma (2008) (87)
- Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (2016) (87)
- Functional CCR9 expression is associated with small intestinal metastasis. (2004) (86)
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial (2022) (85)
- Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes (2016) (84)
- Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma (2010) (84)
- Membrane transport proteins associated with drug resistance expressed in human melanoma. (1995) (83)
- TERT Promoter Mutations Are Frequent in Cutaneous Basal Cell Carcinoma and Squamous Cell Carcinoma (2013) (83)
- Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy (2008) (83)
- Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway (2015) (82)
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker (2013) (80)
- Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing (2020) (79)
- Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark. (2019) (79)
- Melanoma in 2013: Melanoma—the run of success continues (2014) (78)
- Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. (2015) (78)
- Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial. (2010) (78)
- Effects of granulocyte‐macrophage colony‐stimulating factor and foreign helper protein as immunologic adjuvants on the T‐cell response to vaccination with tyrosinase peptides (2003) (78)
- miR-638 promotes melanoma metastasis and protects melanoma cells from apoptosis and autophagy (2014) (77)
- Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG) (2003) (77)
- Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses. (2007) (77)
- Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (2018) (77)
- Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma (2009) (76)
- Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion (2020) (76)
- Genetic and clinico-pathologic analysis of metastatic uveal melanoma (2014) (75)
- A Multimarker Prognostic Assay for Primary Cutaneous Melanoma (2009) (75)
- Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response (2007) (74)
- Intraoperative Fluorescence Imaging for Sentinel Lymph Node Detection: Prospective Clinical Trial to Compare the Usefulness of Indocyanine Green vs Technetium Tc 99m for Identification of Sentinel Lymph Nodes. (2015) (74)
- Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. (2017) (74)
- Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors (2019) (73)
- MiR-101 inhibits melanoma cell invasion and proliferation by targeting MITF and EZH2. (2013) (72)
- Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. (2015) (72)
- Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6‐methylguanine‐DNA methyltransferase and N‐methylpurine‐DNA glycosylase in melanoma cells with acquired drug resistance (1999) (72)
- Expression of interleukin‐8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma (1999) (71)
- Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. (2017) (70)
- Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma (2020) (70)
- Biomarkers in melanoma (2009) (70)
- Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma (2016) (70)
- Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. (2008) (69)
- Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. (2016) (69)
- Genetic alterations and personalized medicine in melanoma: progress and future prospects. (2014) (69)
- Foxp3+ Regulatory T Cells and Natural Killer Cells Distinctly Infiltrate Primary Tumors and Draining Lymph Nodes in Pulmonary Adenocarcinoma (2011) (69)
- The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. (2011) (68)
- Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. (2020) (68)
- Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs (2000) (68)
- COVID-19-Related Fear and Health-Related Safety Behavior in Oncological Patients (2020) (68)
- Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. (2014) (68)
- Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance (2000) (67)
- Melanocortin receptor 1 variants and melanoma risk: A study of 2 European populations (2009) (67)
- Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity (1994) (67)
- Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) (66)
- Candidate genes for cross-resistance against DNA-damaging drugs. (2002) (66)
- Enhanced expression of human ABC‐transporter tap is associated with cellular resistance to mitoxantrone (2001) (66)
- Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors. (2008) (66)
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. (2016) (65)
- Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival (2011) (65)
- Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma. (2011) (65)
- Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. (2002) (65)
- Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles (2018) (65)
- SF3B1 and BAP1 mutations in blue nevus-like melanoma (2017) (65)
- Immunogenicity of Constitutively Active V599EBRaf (2004) (65)
- Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. (2003) (64)
- Health-related quality of life results from the phase III CheckMate 067 study (2017) (64)
- cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. (2003) (64)
- Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. (2020) (63)
- Immunotherapy of distant metastatic disease (2009) (62)
- Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations (2017) (62)
- Skin Melanoma Development in ret Transgenic Mice Despite the Depletion of CD25+Foxp3+ Regulatory T Cells in Lymphoid Organs1 (2009) (61)
- Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype (2004) (61)
- Prevalence of cardiovascular diseases in HIV-infected outpatients: results from a prospective, multicenter cohort study (2013) (61)
- Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq (2016) (61)
- Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study (2012) (61)
- CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. (2021) (60)
- Behavioural conditioning as the mediator of placebo responses in the immune system (2011) (60)
- Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. (2000) (60)
- Tumor type M2 pyruvate kinase (TuM2‐PK) as a novel plasma tumor marker in melanoma (2005) (60)
- Evaluation of a radioactive and fluorescent hybrid tracer for sentinel lymph node biopsy in head and neck malignancies: prospective randomized clinical trial to compare ICG-99mTc-nanocolloid hybrid tracer versus 99mTc-nanocolloid (2015) (60)
- Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen. (2003) (60)
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i (2020) (59)
- Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. (1997) (59)
- High frequencies of circulating melanoma‐reactive CD8+ T cells in patients with advanced melanoma (2000) (59)
- Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. (2018) (59)
- Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients (2018) (58)
- Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. (2014) (57)
- LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial (2020) (57)
- Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. (2021) (56)
- Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies (2007) (56)
- Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. (2012) (55)
- MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series (2019) (55)
- Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system (2016) (55)
- S3‐Guideline “Diagnosis, therapy and follow‐up of melanoma” – short version (2013) (55)
- Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity (2000) (55)
- Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. (2020) (55)
- A first prospective population-based analysis investigating the actual practice of melanoma diagnosis, treatment and follow-up. (2011) (55)
- Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. (2019) (55)
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (54)
- Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. (2000) (54)
- Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort (2015) (54)
- Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. (2006) (54)
- Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors (2011) (53)
- Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. (2017) (53)
- Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. (2016) (53)
- Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two‐dimensional electrophoresis, mass spectrometry and microsequencing (1999) (53)
- Expression of CD44 variant isoforms in malignant melanoma. (1996) (53)
- Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapy (2006) (52)
- NF1 mutations in conjunctival melanoma (2018) (52)
- Melanoma and immunotherapy. (2009) (52)
- Study of the development of chemoresistance in melanoma cell lines using proteome analysis (2003) (52)
- Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: Second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin (2002) (52)
- Good shedder or bad shedder—the influence of skin diseases on forensic DNA analysis from epithelial abrasions (2011) (52)
- Advantages of preoperative hybrid SPECT/CT in detection of sentinel lymph nodes in cutaneous head and neck malignancies (2011) (52)
- Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis? (2009) (52)
- Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe (2017) (52)
- pHH3 Immunostaining Improves Interobserver Agreement of Mitotic Index in Thin Melanomas (2012) (51)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
- Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine (2010) (51)
- Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours (2020) (51)
- Identification of a new HLA‐A*0201‐restricted T‐cell epitope from the tyrosinase‐related protein 2 (TRP2) melanoma antigen (2000) (51)
- Evaluation of T7 and lambda phage display systems for survey of autoantibody profiles in cancer patients. (2008) (51)
- β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. (2013) (51)
- MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. (2018) (51)
- BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. (2014) (50)
- Bacterial colonization of chronic leg ulcers: current results compared with data 5 years ago in a specialized dermatology department (2010) (49)
- Imatinib in melanoma: a selective treatment option based on KIT mutation status? (2007) (49)
- Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. (1996) (49)
- Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) (49)
- Prospective evaluation of follow-up in melanoma patients in Germany - results of a multicentre and longitudinal study. (2015) (49)
- Detection of human papillomaviruses in paraffin-embedded condylomata acuminata--comparison of immunohistochemistry, in situ hybridization, and polymerase chain reaction. (1991) (49)
- Study of Therapy Resistance in Cancer Cells with Functional Proteome Analysis (2002) (48)
- Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. (2016) (48)
- The X-Linked DDX3X RNA Helicase Dictates Translation Reprogramming and Metastasis in Melanoma. (2019) (48)
- Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. (2019) (48)
- Diagnostic biomarkers differentiating metastatic melanoma patients from healthy controls identified by an integrated MALDI‐TOF mass spectrometry/bioinformatic approach (2007) (48)
- Abstract CT075: Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naïve patients with advanced melanoma (CheckMate 067) (2017) (47)
- Differential Endothelial Adhesion Molecule Expression in Early and Late Whealing Reactions (1998) (47)
- Expression of the c‐kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo (1995) (47)
- Investigation of adhesion of modern wound dressings: a comparative analysis of 56 different wound dressings (2011) (47)
- Artificial Intelligence in Skin Cancer Diagnostics: The Patients' Perspective (2020) (47)
- Side effects of systemic oncological therapies in dermatology (2012) (47)
- Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. (2006) (47)
- Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy. (2018) (47)
- Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. (2021) (47)
- Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti‐angiogenic drug resistance? (2011) (47)
- Enhanced P-selectin expression in chronic and dermographic urticaria. (1997) (47)
- Melanoma risk factors, perceived threat and intentional tanning: an international online survey (2010) (46)
- HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. (2019) (46)
- Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance. (2018) (46)
- Activating cysteinyl leukotriene receptor 2 (CYSLTR2) mutations in blue nevi (2017) (46)
- Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. (2014) (46)
- Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma (2017) (46)
- Tumor‐specific antigens in cutaneous T‐cell lymphoma: Expression and sero‐reactivity (2003) (45)
- NAMPT signaling is critical for the proangiogenic activity of tumor‐associated neutrophils (2018) (45)
- mRNA expression of tumor‐associated antigens in melanoma tissues and cell lines (2002) (44)
- Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma. (2016) (44)
- MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome (2010) (44)
- Polidocanol foam sclerotherapy is a new and effective treatment for post‐operative lymphorrhea and lymphocele (2010) (44)
- Increases in Adult Life Expectancy in Rural South Africa : Valuing the Scale-Up of HIV Treatment (44)
- Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). (2019) (44)
- Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study (2016) (44)
- Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (44)
- Radio‐guided surgery: advantages of a new portable γ‐camera (Sentinella®) for intraoperative real time imaging and detection of sentinel lymph nodes in cutaneous malignancies (2012) (43)
- Cell-based vaccination against melanoma – background, preliminary results, and perspective (1999) (43)
- Photoreceptor proteins as cancer‐retina antigens (2007) (43)
- Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
- Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe. (2016) (43)
- The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma (2006) (42)
- Cutaneous large B‐cell lymphoma of the leg masquerading as a chronic venous ulcer (2002) (42)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (42)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study (2019) (42)
- Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients (2004) (42)
- Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. (1998) (42)
- Endogenous μ‐opioid peptides modulate immune response towards malignant melanoma (2011) (42)
- GBP-5 splicing variants: New guanylate-binding proteins with tumor-associated expression and antigenicity. (2004) (42)
- Sex differences in oncogenic mutational processes (2019) (41)
- Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). (2015) (41)
- P‐glycoprotein expression in primary and metastatic malignant melanoma (1995) (41)
- Results of COLUMBUS Part 2: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus ENCO in BRAF - Mutant Melanoma (2017) (41)
- Substance use and sexual risk behaviour among HIV‐positive men who have sex with men in specialized out‐patient clinics (2012) (40)
- Linac-Based Radiosurgery of Cerebral Melanoma Metastases (2003) (40)
- Primary Extracutaneous Malignant Melanoma: A Comprehensive Review with Emphasis on Treatment (2004) (40)
- Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells. (2010) (39)
- Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies (2019) (39)
- Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma (2022) (39)
- mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study (2014) (39)
- Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (39)
- Risk loci for coronary artery calcification replicated at 9p21 and 6q24 in the Heinz Nixdorf Recall Study (2013) (38)
- Glutathione and related enzymes in tumor progression and metastases of human melanoma. (1995) (38)
- Childhood Psoriasis—An Analysis of German Health Insurance Data (2014) (38)
- Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. (2019) (38)
- Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. (2021) (38)
- Telomere length, telomerase reverse transcriptase promoter mutations, and melanoma risk (2018) (38)
- Dose-dependent severe cutaneous reactions to imatinib (2003) (38)
- Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma (2018) (38)
- Drug Resistance in Human Melanoma: Mechanisms and Therapeutic Opportunities (2003) (38)
- SEREX identification of new tumor antigens linked to melanoma‐associated retinopathy (2005) (38)
- Cutaneous melanoma: A model to study cancer metastasis (2011) (38)
- Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. (2019) (37)
- Photoacoustic imaging of real-time oxygen changes in chronic leg ulcers after topical application of a haemoglobin spray: a pilot study. (2016) (37)
- Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. (2017) (37)
- Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. (2017) (37)
- Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. (1996) (37)
- Serum manganese superoxide dismutase is a new tumour marker for malignant melanoma (1995) (37)
- Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. (2016) (37)
- Autologous dendritic cells for treatment of advanced cancer--an update. (2001) (37)
- Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. (2006) (37)
- Identification of tumor antigens and T-cell epitopes, and its clinical application (2004) (37)
- TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma (2021) (37)
- SEREX identification of new tumour‐associated antigens in cutaneous T‐cell lymphoma (2004) (37)
- Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma (2014) (36)
- First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis (2019) (36)
- Recoverin as a cancer-retina antigen (2006) (36)
- Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group (2007) (36)
- Association between the germline MC1R variants and somatic BRAF/NRAS mutations in melanoma tumors. (2010) (35)
- Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma. (2009) (35)
- Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment (2002) (35)
- Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations (2015) (35)
- Photoaging Mobile Apps as a Novel Opportunity for Melanoma Prevention: Pilot Study (2017) (35)
- Cancer‐retina antigens as potential paraneoplastic antigens in melanoma‐associated retinopathy (2009) (35)
- Actinic keratoses treated with cold atmospheric plasma (2018) (35)
- Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. (2000) (35)
- Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. (2020) (35)
- Cognitive Factors Mediate Placebo Responses in Patients with House Dust Mite Allergy (2013) (34)
- Verrucous cysts: histopathologic characterization and molecular detection of human papillomavirus‐specific DNA (1993) (34)
- Indocyanine green fluorescence‐guided sentinel lymph node biopsy in dermato‐oncology (2012) (34)
- Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials. (2019) (34)
- A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope. (2005) (34)
- Analysis of mast cell subpopulations (MCT, MCTC) in cutaneous inflammation using novel enzyme‐histochemical staining techniques (1994) (33)
- Linac-based radiosurgery of cerebral melanoma metastases. Analysis of 122 metastases treated in 64 patients. (2003) (33)
- Patterns of constitutive and IFN-γ inducible expression of HLA class II molecules in human melanoma cell lines (2007) (33)
- Interleukin‐6 expression in the skin of patients with lupus erythematosus (1995) (33)
- Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. (2020) (33)
- Melanoma brain metastases - Interdisciplinary management recommendations 2020. (2020) (33)
- Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis. (2020) (33)
- CD44 variant isoform expression in a variety of skin-associated autoimmune diseases. (1998) (33)
- The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I. (2019) (32)
- Single-nucleotide polymorphisms in DNA-repair genes and cutaneous melanoma. (2010) (32)
- Identification of selectively expressed genes and antigens in CTCL (2008) (32)
- Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination. (2012) (32)
- Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data. (2019) (32)
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. (2014) (32)
- Genese des chronischen Ulcus cruris bei 31 619 Patienten im Rahmen einer Expertenbefragung in Deutschland (2011) (32)
- Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. (2019) (31)
- Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. (2014) (31)
- Expression of SCF splice variants in human melanocytes and melanoma cell lines: potential prognostic implications (2000) (31)
- Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma. (2017) (31)
- Expression of CD44 splice variants in human skin and epidermal tumours (1996) (31)
- Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. (2014) (31)
- Clinical Phase II Study of Pegylated Liposomal Doxorubicin as Second-Line Treatment in Disseminated Melanoma (2004) (31)
- cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells (2009) (30)
- Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma (2020) (30)
- Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. (2022) (30)
- Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma (2020) (30)
- Interleukin‐7. Biology and implications for dermatology (1996) (29)
- Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms” (2013) (29)
- The new face of nucleolin in human melanoma (2009) (29)
- Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma (2003) (29)
- Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification. (2021) (29)
- Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis (2016) (29)
- Kurzleitlinie – Malignes Melanom der Haut (2006) (29)
- Break-MB: a phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) (2012) (29)
- The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma (2018) (29)
- Humoral immune response against melanoma antigens induced by vaccination with cytokine gene‐modified autologous tumor cells (2004) (29)
- Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing (2018) (29)
- Quality assurance for care of melanoma patients based on guideline‐derived quality indicators and certification (2014) (28)
- Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates (2004) (28)
- A Skin Cancer Prevention Facial-Aging Mobile App for Secondary Schools in Brazil: Appearance-Focused Interventional Study (2018) (28)
- Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up. (2020) (28)
- Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients (2018) (28)
- Association of genomic imbalances with resistance to therapeutic drugs in human melanoma cell lines (2000) (28)
- Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. (2020) (28)
- Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. (2019) (28)
- Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis (2021) (28)
- Integrating first-line treatment options into clinical practice: what’s new in advanced melanoma? (2015) (28)
- Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. (2015) (28)
- ERCC5 p.Asp1104His and ERCC2 p.Lys751Gln polymorphisms are independent prognostic factors for the clinical course of melanoma. (2011) (28)
- Vaccination of melanoma patients with peptide-pulsed dendritic cells: 047 (1997) (27)
- Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). (2019) (27)
- Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib (2003) (27)
- Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma (2016) (27)
- [Brief guidelines: malignant melanoma of the skin]. (2006) (27)
- Clinical and genetic analysis of melanomas arising in acral sites. (2019) (27)
- Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment (2021) (27)
- Inherited variation in the PARP1 gene and survival from melanoma (2014) (26)
- PLX4032: does it keep its promise for metastatic melanoma treatment? (2010) (26)
- Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients (2020) (26)
- Reliability and cost‐effectiveness of sentinel lymph node excision under local anaesthesia versus general anaesthesia for malignant melanoma: a retrospective analysis in 300 patients with malignant melanoma AJCC Stages I and II (2011) (26)
- Surveillance and Follow-up Examinations in Cutaneous Melanoma (2003) (26)
- Prognostic significance of spontaneous antibody responses against tumor‐associated antigens in malignant melanoma patients (2015) (26)
- Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. (2014) (26)
- Amelanotic malignant melanoma presenting as malignant schwannoma (1993) (26)
- Effects of Label Noise on Deep Learning-Based Skin Cancer Classification (2020) (26)
- Human melanoma: drug resistance. (2003) (26)
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. (2019) (26)
- Frequent occurrence of high affinity T cells against MELOE‐1 makes this antigen an attractive target for melanoma immunotherapy (2010) (26)
- Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient. (2012) (25)
- The Efficiency of Human Cytomegalovirus pp65495–503 CD8+ T Cell Epitope Generation Is Determined by the Balanced Activities of Cytosolic and Endoplasmic Reticulum-Resident Peptidases (2012) (25)
- Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. (2004) (25)
- Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients (2002) (25)
- Tumor-associated Antigens as Possible Targets for Immune Therapy in Head and Neck Cancer: Comparative mRNA Expression Analysis of RAGE and GAGE Genes (2002) (25)
- Expression of GAGE family proteins in malignant melanoma. (2007) (25)
- Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC). (2019) (25)
- Update on the clinical use of kinase inhibitors in melanoma (2017) (25)
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). (2012) (25)
- Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. (2011) (25)
- Genes involved in the WNT and vesicular trafficking pathways are associated with melanoma predisposition (2015) (25)
- The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. (2021) (24)
- Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. (2009) (24)
- Effects of various synthetic retinoids on proliferation and immunophenotype of human melanoma cells in vitro. (1995) (24)
- Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2007) (24)
- Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient’s choice: a multicentre Dermatologic Cooperative Oncology Group trial (2011) (24)
- Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? (2018) (24)
- Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. (2014) (24)
- Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain (2020) (24)
- Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance. (2014) (24)
- Integrated molecular drivers coordinate biological and clinical states in melanoma (2020) (24)
- Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. (2019) (24)
- Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915) (2021) (24)
- EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up. (2011) (24)
- Phenotypic characterization and prognostic impact of circulating γδ and αβ T‐cells in metastatic malignant melanoma (2016) (23)
- Current advances and perspectives in the treatment of advanced melanoma (2012) (23)
- New developments in biomarkers for melanoma (2013) (23)
- Integrating Patient Data Into Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review (2021) (23)
- A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. (2006) (23)
- High TERT promoter mutation frequency in non‐acral cutaneous metastatic melanoma (2016) (23)
- Elevated MIA serum levels are of relevance for management of metastasized malignant melanomas: results of a German multicenter study. (2000) (23)
- S3‐Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms – Update 2015/2016, Kurzversion 2.0 (2017) (23)
- Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (23)
- Is There a Standard for the Palliative Treatment of Melanoma? (2002) (23)
- Activating CYSLTR2 and PLCB4 Mutations in Primary Leptomeningeal Melanocytic Tumors. (2017) (23)
- Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling (2018) (23)
- Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma (2021) (23)
- Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial. (2015) (23)
- Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. (2018) (23)
- Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. (2011) (23)
- Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts (2020) (23)
- HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model (2017) (23)
- Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia. (2015) (22)
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis (2020) (22)
- Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment (2018) (22)
- PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): A pooled analysis (2016) (22)
- Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA (2016) (22)
- Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes (2006) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy (2020) (22)
- Photoaging Mobile Apps in School-Based Melanoma Prevention: Pilot Study (2017) (22)
- Statin use and its effect on all-cause mortality of melanoma patients: a population-based Dutch cohort study (2014) (21)
- Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group (2008) (21)
- Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib. (2020) (21)
- Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53 (2020) (21)
- Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells. (1994) (21)
- Brain metastasis: opportunity for drug development? (2012) (21)
- Targeting the H3K4 demethylase KDM5B reprograms the metabolome and phenotype of melanoma cells. (2019) (21)
- IL-12 Production by Human Monocyte-Derived Dendritic Cells: Looking at the Single Cell (2005) (21)
- An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study (2013) (21)
- Primary leiomyosarcoma of the skin. A histological and immunohistochemical analysis. (1993) (21)
- METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM). (2012) (21)
- A Medical Student-Delivered Smoking Prevention Program, Education Against Tobacco, for Secondary Schools in Germany: Randomized Controlled Trial (2017) (21)
- Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. (2018) (21)
- 5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma (2019) (21)
- Subacute cutaneous lupus erythematosus on the lines of Blaschko. (2006) (21)
- The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2016) (21)
- Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. (2015) (21)
- Schmerzreduktion bei Patienten mit chronischem Ulcus cruris durch ein neu entwickeltes Morphingel (2011) (20)
- Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity. (2013) (20)
- Lack of SF3B1 R625 mutations in cutaneous melanoma (2013) (20)
- Efficacy and safety of nivolumab (NIVO) in patients with advanced melanoma (MEL) and poor prognostic factors who progressed on or after ipilimumab (IPI): Results from a phase II study (CheckMate 172). (2017) (20)
- Nine‐year follow‐up of a case of Grzybowski type multiple keratoacanthomas and failure to demonstrate human papillomavirus (2002) (20)
- Combining BRAFV600E inhibition with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma (2015) (20)
- MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma (2004) (19)
- A rare primary sellar melanoma. Case report. (2004) (19)
- Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2–Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice (2005) (19)
- Endoprotease profiling with double-tagged peptide substrates: a new diagnostic approach in oncology. (2010) (19)
- Abstract CT037: Genomic analyses and immunotherapy in advanced melanoma (2019) (19)
- Advances and perspectives in immunotherapy of melanoma. (2012) (19)
- Dacarbacine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) as first-line treatment of patients with metastatic melanoma: Results of a prospective-randomized phase III study. (2004) (19)
- Systemic therapies for melanoma brain metastases: which drug for whom and when? (2015) (19)
- Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry. (2019) (19)
- A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. (2015) (19)
- Assessment of Nonradioactive Multispectral Optoacoustic Tomographic Imaging With Conventional Lymphoscintigraphic Imaging for Sentinel Lymph Node Biopsy in Melanoma (2019) (19)
- GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma (2020) (19)
- CEACAM1-3S Drives Melanoma Cells into NK Cell-Mediated Cytolysis and Enhances Patient Survival. (2015) (19)
- Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. (2020) (18)
- Exposure to Melan-A/MART-126-35 tumor epitope specific CD8+T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS) (2016) (18)
- Steroid‐induced Periorificial Dermatitis in Children—Clinical Features and Response to Azelaic Acid (2010) (18)
- Antitumor activity of miR-1280 in melanoma by regulation of Src. (2015) (18)
- Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells. (1994) (18)
- Robustness of convolutional neural networks in recognition of pigmented skin lesions. (2021) (18)
- Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries (2010) (18)
- Prolongation of the QTc interval in HIV-infected individuals compared to the general population (2017) (18)
- Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplati (2002) (18)
- Re: Association between endothelin receptor B nonsynonymous variants and melanoma risk. (2006) (18)
- Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma (2008) (18)
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) (18)
- [Causes of leg ulcers. Analysis of the data from a dermatologic wound care center]. (2009) (18)
- Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma (2022) (18)
- Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts (2016) (18)
- Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells (2000) (18)
- Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. (2016) (18)
- Disseminated cutaneous Kaposi sarcoma and progressive multifocal leukoencephalopathy in a patient with idiopathic CD4+ T lymphocytopenia. (2007) (18)
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC study. (2013) (17)
- Management of gastrointestinal (GI) toxicity associated with nivolumab (NIVO) plus ipilimumab (IPI) or IPI alone in phase II and III trials in advanced melanoma (MEL). (2017) (17)
- A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma (2018) (17)
- Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. (2021) (17)
- LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA (2014) (17)
- Vitamin A metabolism in benign and malignant melanocytic skin cells: Importance of lecithin/retinol acyltransferase and RPE65 (2012) (17)
- Effect of a Face-Aging Mobile App–Based Intervention on Skin Cancer Protection Behavior in Secondary Schools in Brazil (2020) (17)
- Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic anti-tumor activity. (2019) (17)
- Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma (2017) (17)
- Trametinib-Induced Remission of an MEK1-Mutated Langerhans Cell Histiocytosis. (2017) (17)
- Blood T‐cell Vβ transcriptome in melanoma patients (2004) (17)
- Complete remission of multiple satellite and in‐transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod (2006) (17)
- Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients (2019) (17)
- A benchmark for neural network robustness in skin cancer classification. (2021) (17)
- PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. (2018) (16)
- Inherited functional variants of the lymphocyte receptor CD5 influence melanoma survival (2016) (16)
- Long-term benefit of adjuvant dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF V600–mutant melanoma: Five-year analysis of COMBI-AD. (2020) (16)
- 1213OCharacterization of complete responses (CRs) in patients with advanced melanoma (MEL) who received the combination of nivolumab (NIVO) and ipilimumab (IPI), NIVO or IPI alone (2017) (16)
- LBA35OVERALL SURVIVAL AND BIOMARKER RESULTS FROM A PHASE 2 STUDY OF MEK1/2 INHIBITOR BINIMETINIB (MEK162) IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA (2014) (16)
- Mental Health Burden of German Cancer Patients before and after the Outbreak of COVID-19: Predictors of Mental Health Impairment (2021) (16)
- Facial-Aging App Availability in Waiting Rooms as a Potential Opportunity for Skin Cancer Prevention (2018) (16)
- Seroreactivity against MAGE‐A and LAGE‐1 proteins in melanoma patients (2003) (16)
- [A new topically applied morphine gel for the pain treatment in patients with chronic leg ulcers: first results of a clinical investigation]. (2011) (16)
- Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma (2003) (16)
- Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression (2017) (16)
- Gene-based therapy of malignant melanoma. (2002) (16)
- Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter. (1995) (16)
- Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis (2022) (16)
- Fear of cancer progression in patients with stage IA malignant melanoma (2018) (15)
- A skin cancer prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised controlled trial (2018) (15)
- Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy (2012) (15)
- Isolated cerebral susceptibility artefacts in patients with malignant melanoma: metastasis or not? (2013) (15)
- The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. (2006) (15)
- Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. (2010) (15)
- T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma (2012) (15)
- Patient-reported outcomes with nivolumab in advanced solid cancers. (2018) (15)
- Mast cells in melanocytic tumours (2004) (15)
- Industrial Forum · Industrieforum (2001) (15)
- Human c-myb is expressed in cervical carcinomas and transactivates the HPV-16 promoter. (1995) (15)
- Integrin genes and susceptibility to human melanoma. (2012) (15)
- A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic (2018) (14)
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. (2022) (14)
- Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600-mutant stage III melanoma. (2018) (14)
- Unmet information needs of patients with melanoma in Germany (2019) (14)
- Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. (2016) (14)
- Peroxisome proliferator-activating receptors: a new way to treat melanoma? (2009) (14)
- Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab (2017) (14)
- Information‐seeking and use of information resources among melanoma patients of German skin cancer centers (2018) (14)
- Progression of malignant melanoma is associated with reduced 25‐hydroxyvitamin D serum levels (2008) (14)
- Explainable artificial intelligence in skin cancer recognition: A systematic review. (2022) (14)
- IRF4 rs12203592 functional variant and melanoma survival (2017) (14)
- Detection of abacavir hypersensitivity by ELISpot method. (2012) (14)
- Imatinib in locally advanced dermatofibrosarcoma protuberans (DFSP): A phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2006) (14)
- Conjunctival Melanomas Harbor BRAF and NRAS Mutations—Response (2013) (14)
- Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma. (2019) (14)
- Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma? (2018) (14)
- Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine (2002) (14)
- Arenavirus Induced CCL5 Expression Causes NK Cell-Mediated Melanoma Regression (2020) (14)
- A smoking prevention photoageing intervention for secondary schools in Brazil delivered by medical students: protocol for a randomised trial (2017) (14)
- Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing (2001) (14)
- DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma. (2011) (14)
- Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT (2011) (14)
- Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours. (2021) (14)
- The phosphatidyl inositol 3‐kinase pathway is central to the pathogenesis of Kit‐activated melanoma (2011) (14)
- Blood T-cell Vbeta transcriptome in melanoma patients. (2004) (13)
- LBA7_PRBRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence (2017) (13)
- SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma (2016) (13)
- Differentiation of monocyte-derived dendritic cells under the influence of platelets. (2008) (13)
- Reliability and cost‐effectiveness of complete lymph node dissection under tumescent local anaesthesia vs. general anaesthesia: a retrospective analysis in patients with malignant melanoma AJCC stage III (2012) (13)
- Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology. (2019) (13)
- Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047) (2022) (13)
- Health-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. (2018) (13)
- CA224-047: A randomized, double-blind, phase II/III study of relatlimab (anti-LAG-3) in combination with nivolumab (anti-PD-1) versus nivolumab alone in previously untreated metastatic or unresectable melanoma. (2018) (13)
- Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study (2021) (13)
- Intracerebral metastases of malignant melanoma and their recurrences—A clinical analysis (2013) (13)
- Melanoma patients respond to a new HLA‐A*01‐presented antigenic ligand derived from a multi‐epitope region of melanoma antigen TRP‐2 (2005) (13)
- PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer (2018) (13)
- Retinoic Acid receptor-gamma-selective retinoids exert antiproliferative effects on human-melanoma cell-growth in-vitro. (1994) (13)
- Visible Light Modulates the Expression of Cancer-Retina Antigens (2008) (13)
- Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma? (2016) (13)
- The polymerase chain reaction. Method and applications in dermatopathology. (1993) (13)
- Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV‐positive men who have sex with men (MSM) – approaches for medical prevention (2017) (13)
- Effect of ipilimumab at 10 mg/kg on disease control in patients (pts) with M1c-stage melanoma in relation to baseline lactate dehydrogenase (LDH) levels. (2009) (13)
- Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: A multicenter phase II DeCOG trial. (2010) (13)
- Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al. (2015) (13)
- Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB-IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study. (2018) (13)
- Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG “GERMELATOX survey”) versus melanoma recurrence to quantify patients’ relative values for adjuvant therapy (2016) (12)
- Analysis of SDHD promoter mutations in various types of melanoma (2015) (12)
- Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients (2003) (12)
- In vivo selective expansion of a tumour‐specific cytotoxic T‐cell clone derived from peripheral blood of a melanoma patient after vaccination with gene‐modified autologous tumour cells (1999) (12)
- Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advancedBRAFV600-mutant melanoma: First efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i (2018) (12)
- MITF is a critical regulator of the carcinoembryonic antigen‐related cell adhesion molecule 1 (CEACAM1) in malignant melanoma (2015) (12)
- Melanoma diagnosed in lesions previously treated by laser therapy (2017) (12)
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. (2019) (12)
- A novel heteromorphic human cell surface alloantigen, gp60, defined by a human monoclonal antibody. (1989) (12)
- Treatment Algorithms in Stage IV Melanoma (2015) (12)
- T CELL REPERTOIRE IN COMBINATION WITH T CELL DENSITY PREDICTS CLINICAL OUTCOMES IN PATIENTS WITH MERKEL CELL CARCINOMA. (2020) (12)
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma : Comparison with Regulatory T Cells and NY-ESO-1-or MelanA – Speci fi c T Cells (2014) (12)
- Characterization of gene regulatory elements for selective gene expression in human melanoma cells. (1995) (12)
- Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the interleukin-7 gene to autologous and allogeneic immunologic effector cells. (1997) (12)
- Advantages of preoperative ultrasound in conjunction with lymphoscintigraphy in detecting malignant melanoma metastases in sentinel lymph nodes: a retrospective analysis in 221 patients with malignant melanoma AJCC Stages I and II (2012) (12)
- The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific (2006) (12)
- A rare case of primary sellar melanoma (2009) (12)
- Retarded low‐dose doxycycline for EGFR or MEK inhibitor–induced papulopustular rash (2014) (12)
- In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons (1994) (11)
- Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study. (2012) (11)
- Immunoscreening of a cutaneous T-cell lymphoma library for plasma membrane proteins (2007) (11)
- NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. (2014) (11)
- LBA3 Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial (2021) (11)
- Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma (2019) (11)
- Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors? (2019) (11)
- Adjuvante Interferon-α-Therapie beim Melanom Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (1998) (11)
- BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes (2020) (11)
- Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs (2006) (11)
- Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma. (2020) (11)
- Responsiveness to interferon treatment of human melanoma cells correlates to immunophenotype. (1993) (11)
- S3‐Leitlinie ,,Diagnostik, Therapie und Nachsorge des Melanoms” – Kurzfassung (2013) (11)
- Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma (2022) (11)
- Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma (2021) (11)
- The predictive and prognostic significance of cell‐free DNA concentration in melanoma (2020) (11)
- Genese des Ulcus cruris (2009) (11)
- Jo-1 positive paraneoplastic systemic sclerosis in a patient with metastatic melanoma. (2006) (11)
- Role of Elevated PHIP Copy Number as a Prognostic and Progression Marker for Cutaneous Melanoma (2018) (11)
- Nodular scabies: hypersensitivity reaction or infection? (2011) (11)
- The prognostic value of sentinel lymph nodes on distant metastasis-free survival in patients with high-risk squamous cell carcinoma. (2019) (10)
- Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED) (2019) (10)
- Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma (2013) (10)
- Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. (2017) (10)
- Integrative Genomic Analyses of Patient-Matched Intracranial and Extracranial Metastases Reveal a Novel Brain-Specific Landscape of Genetic Variants in Driver Genes of Malignant Melanoma (2021) (10)
- Comparison of non-viral transfection methods in melanoma cell primary cultures. (2000) (10)
- Local cutaneous argyria mimicking melanoma metastases in a patient with disseminated melanoma. (2006) (10)
- The clinical course of steroid-sensitive childhood nephrotic syndrome is associated with a functional IL12B promoter polymorphism. (2008) (10)
- Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1 (2020) (10)
- Interleukin 21 augments the hepatitis B virus-specific CD8+ T-cell response in vitro in patients coinfected with HIV-1 (2012) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067. (2022) (10)
- Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. (2018) (10)
- Oxygenation Status in Chronic Leg Ulcer After Topical Hemoglobin Application May Act as a Surrogate Marker to Find the Best Treatment Strategy and to Avoid Ineffective Conservative Long-term Therapy (2018) (10)
- A Dermatologist's Ammunition in the War Against Smoking: A Photoaging App (2017) (10)
- Combined treatment of stage IV melanoma patients with amifostine and fotemustine — a pilot study (1998) (10)
- Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAFV600 mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial. (2021) (10)
- 1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (10)
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) (2022) (10)
- Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma (2016) (10)
- Phase II study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC) (2019) (10)
- Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG (2020) (9)
- Sentinel lymph node excision with or without preoperative hybrid single-photon emission computed tomography/computed tomography (SPECT/CT) in melanoma: study protocol for a multicentric randomized controlled trial (2019) (9)
- Gene amplification by polymerase chain reaction in dermatology. (1991) (9)
- 1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS. (2014) (9)
- SIRT1‐mediated deacetylation of FOXO3a transcription factor supports pro‐angiogenic activity of interferon‐deficient tumor‐associated neutrophils (2021) (9)
- Persister state-directed transitioning and vulnerability in melanoma (2020) (9)
- Frequent Occurrence of NRAS and BRAF Mutations in Human Acral Naevi (2019) (9)
- Mixed effect modelling of proteomic mass spectrometry data by using Gaussian mixtures (2010) (9)
- Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks (2015) (9)
- Expanded access programmes: patient interests versus clinical trial integrity. (2015) (9)
- Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial (2018) (9)
- Vemurafenib improves overall survival compared to dacarbazine in advanced BRAFV600E mutated melanoma: an update from the phase III randomized, open-label, multicenter BRIM3 trial (2011) (9)
- Intermittent high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Final analysis of a randomized phase III DeCOG-trial (NCT00226408). (2008) (9)
- The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression (2016) (9)
- Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups. (2014) (9)
- COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma (2022) (9)
- Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. (2018) (9)
- Diagnosing a Primary Leptomeningeal Melanoma by Gene Mutation Signature. (2016) (9)
- 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone (2020) (9)
- Long-term safety and overall survival update for BREAK-2, a phase 2, single-arm, open-label study of dabrafenib in previously treated metastatic melanoma (NCT01153763). (2014) (9)
- GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors (2021) (9)
- BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419). (2014) (9)
- Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. (2021) (9)
- Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. (2014) (9)
- Vitiligo expansion and extent correlate with durable response in anti‐programmed death 1 antibody treatment for advanced melanoma: A multi‐institutional retrospective study (2020) (9)
- Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: Findings from the COMBI-AD trial analyzed based on AJCC 8 classification. (2018) (9)
- Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. (2020) (8)
- Immunotherapy in non-melanoma skin cancer: updates and new perspectives (2019) (8)
- Photopheresis in pediatric patients with low‐body weight using the UVAR® XTS™ system (2009) (8)
- Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection (2015) (8)
- Giant pilomatricoma: a benign tumor in an uncommon presentation. (2009) (8)
- Effect of the farnesyl transferase inhibitor lonafarnib on sensitivity of melanoma cells to the multikinase inhibitor sorafenib and on Rheb farnesylation and mTOR signaling. (2016) (8)
- Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (8)
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (8)
- Willingness to pay for a cure of low-risk melanoma patients in Germany (2018) (8)
- Interferon‐γ downregulates epidermal growth factor receptors on human melanoma cells (1995) (8)
- Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis (2021) (8)
- Is there a role for immune checkpoint blockade in metastatic uveal melanoma? (2015) (8)
- The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. (2020) (8)
- Role of apaf-1 in melanoma drug resistance and apoptosis. (2005) (8)
- Valvular manifestations of human immunodeficiency virus infection – results from the prospective, multicenter HIV-HEART study (2013) (8)
- Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities. (2021) (8)
- Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells (2005) (8)
- Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial (2022) (7)
- Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. (2021) (7)
- 9308 Activity of ipilimumab at 10 mg/kg in patients with advanced melanoma is independent of baseline prognostic factors (2009) (7)
- CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma (2015) (7)
- MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas. (2014) (7)
- Long-Term Outcomes in Patients With BRAF V 600-Mutant Metastatic Melanoma Receiving Dabrafenib Monotherapy : Analysis From Phase 2 and 3 Clinical Trials (2021) (7)
- Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response (2020) (7)
- Primary tumor versus metastasis: new experimental models for studies on cancer cell homing and metastasis in melanoma (2014) (7)
- Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. (2006) (7)
- 1222PDRegional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067) (2017) (7)
- [Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy]. (1993) (7)
- Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. (2017) (7)
- Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology (2020) (7)
- Somatic gene therapy and its implications in melanoma treatment (1997) (7)
- Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). (2018) (7)
- Clinical Features and Classification (2013) (7)
- NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. (2021) (7)
- Expectation‐induced placebo responses fail to accelerate wound healing in healthy volunteers: results from a prospective controlled experimental trial (2015) (7)
- Gene-based immunotherapy of skin cancers. (2002) (7)
- Interleukin 7 trials for melanoma treatment. (1996) (7)
- Classical and variant Merkel cell carcinoma cell lines display different degrees of neuroendocrine differentiation and epithelial-mesenchymal transition. (2021) (7)
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. (2021) (7)
- Tumor regression and sirolimus-based therapy in lung transplantation. (2013) (7)
- Acute monoblastic leukemia with skin nodules in an adult. (1993) (7)
- Human CD4+ T Lymphocytes Recognize a Vascular Endothelial Growth Factor Receptor-2–Derived Epitope in Association with HLA-DR (2008) (6)
- Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma (1995) (6)
- [External scientific evaluation of the first teledermatology app without direct patient contact in Germany (Online Dermatologist-AppDoc)]. (2020) (6)
- New promises in the adjuvant, and palliative treatment of melanoma. (2007) (6)
- Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. (2014) (6)
- DIG-labeled RNA in situ hybridization without coverslipping. (1995) (6)
- Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma (2018) (6)
- Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. (2019) (6)
- Oncocardiology: new challenges, new opportunities (2020) (6)
- Externe wissenschaftliche Evaluation der ersten Teledermatologie-App ohne direkten Patientenkontakt in Deutschland („Online Hautarzt – AppDoc“) (2020) (6)
- Utilizing Artificial Neural Networks to Elucidate Serum Biomarker Patterns Which Discriminate Between Clinical Stages in Melanoma (2005) (6)
- Systemic Treatment in Advanced Melanoma: Innovative Perspectives (2003) (6)
- Sources of information and support for melanoma patients: differences between patients' and clinicians' preferences (2019) (6)
- Segregation of Effector Mechanisms in a Tumour‐Specific CD8+ T‐Cell Clone Correlates with CD30 Expression (2001) (6)
- Oncogene Status of an Interdigitating Dendritic Cell Sarcoma: Recurrent Mutations in NF1, TP53, and ARID2 Shared With Melanoma. (2016) (6)
- Dose-dependent toxicity of ipilimumab in metastatic melanoma. (2018) (6)
- BRAF inhibitor acquired resistance: A multicenter meta-analysis of the spectrum and clinical implications of resistance mechanisms. (2015) (6)
- Proteomics for biomarker discovery in malignant melanoma (2008) (6)
- Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600–mutant melanoma. (2019) (6)
- STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-&agr; (2018) (6)
- Multi-modal pooled Perturb-CITE-Seq screens in patient models define novel mechanisms of cancer immune evasion (2020) (6)
- The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians (2018) (6)
- Immuntherapie beim malignen Melanom (2020) (6)
- Antiretroviral therapy suppresses rectal HIV-RNA shedding despite inflammation in MSM with rectal C. trachomatis and N. gonorrhoeae infections—a cross-sectional, single-center study (2018) (6)
- Preliminary study of micromechanical stress delivery for cell biology studies (2007) (6)
- BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management (2014) (6)
- Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. (2016) (6)
- Prognostic factors for pulmonary metastasectomy in malignant melanoma: size matters. (2019) (6)
- The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. (2013) (6)
- Adjuvante Interferon α− Therapie beim Melanom (1998) (6)
- Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance (2016) (6)
- Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity (2021) (6)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (5)
- Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAFV600-positive melanoma: Interim analysis of the ImmunoCobiVem study. (2022) (5)
- Identification of HLA class I dependent immunogenic peptides from clonotypic TCRβ expressed in cutaneous T‐cell lymphoma (2006) (5)
- Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma. (2021) (5)
- Actual practice of melanoma follow‐up and treatment in Germany: results of a prospective, longitudinal cohort study (2015) (5)
- How melanoma is treated in real life. (2008) (5)
- Expression of VLA-4 on primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels correlates with clinical outcome (2007) (5)
- Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study (2021) (5)
- ER‐aminopeptidase 1 determines the processing and presentation of an immunotherapy‐relevant melanoma epitope (2019) (5)
- ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry (2020) (5)
- Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients (2021) (5)
- regulatory T cells impairs mouse melanoma growth (2012) (5)
- [Psoriasis in children and adolescents. A nationwide physician survey on the healthcare situation in Germany]. (2012) (5)
- Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8+ tumor-infiltrating lymphocytes. (2021) (5)
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma (2022) (5)
- Sunday, 26 August 2012 (2012) (5)
- Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600–mutant melanoma. (2017) (5)
- STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. (2022) (5)
- Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy. (2021) (5)
- MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study. (2022) (5)
- CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. (2022) (5)
- Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report (2020) (5)
- Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. (2022) (5)
- Altered surface expression patterns of circulating monocytes in cancer patients: impaired capacity of T-cell stimulation? (2004) (5)
- The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. (2020) (5)
- Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). (2021) (5)
- Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater‐blinded study (ACTICAP) (2020) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Release of stem cell factor during differentiation of human hacat keratinocytes (1994) (5)
- B08CheckMate 067: a phase III randomized double-blind study of nivolumab (NIVO) monotherapy or NIVO combined with ipilimumab (IPI) versus IPI monotherapy in previously untreated patients (pts) with advanced melanoma (MEL) (2015) (5)
- Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real‐world conditions in Germany – The non‐interventional study NIELS (2021) (5)
- Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (5)
- Multicentre study on standardisation of melanoma cell culture – an initiative of the German Melanoma Research Network (2010) (5)
- Mikie: A randomized, double-blinded, regimen-controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs). (2016) (5)
- Complex Formation with Monomeric α-Tubulin and Importin 13 Fosters c-Jun Protein Stability and Is Required for c-Jun’s Nuclear Translocation and Activity (2019) (5)
- Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. (2021) (4)
- Identification of a cross-reactive HLA-DRB1*0301-restricted CD4 T cell response directed against cholesterol-binding cytolysins from two different pathogens. (2006) (4)
- Chemoresistance of malignant melanoma. Mechanisms and possible modulation (1994) (4)
- Overall survival at 4 years of follow-up in a phase III trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067). (2018) (4)
- Durchführung der Photopherese bei pädiatrischen Patienten mit niedrigem Körpergewicht mit dem UVAR® XTS™ System (2009) (4)
- Myeloid-derived suppressor cells predict survival of advanced melanoma patients : comparison with regulatory T cells and NY-ESO-1-or MelanA-specific T cells (2013) (4)
- Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report. (1998) (4)
- Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma. (2017) (4)
- Detection of Spontaneous CD 4 + T-Cell Responses inMelanoma Patients against a Tyrosinase-Related Protein-2 ^ Derived Epitope Identified in HLA-DRB 1 * 0301 TransgenicMice (2005) (4)
- Advances in the Treatment of Advanced Extracutaneous Melanomas and Nonmelanoma Skin Cancers. (2017) (4)
- Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry (2021) (4)
- Quality‐of‐life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient‐reported outcomes from the MIKIE study (2020) (4)
- Hypomelanosis due to block of melanosomal maturation in amiodarone-induced hyperpigmentation. (2001) (4)
- [Interdisciplinary management of cutaneous adverse events of EGFR inhibitors and multityrosine kinase inhibitors in oncology]. (2011) (4)
- Perianale Ulzerationen durch Kaliumpermanganatbäder (2010) (4)
- Tumor-specific circulating cell-free DNA (cfDNA) BRAF mutations (muts) to predict clinical outcome in patients (pts) treated with the BRAF inhibitor dabrafenib (GSK2118436). (2012) (4)
- Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma. (2013) (4)
- Clinical application of noninvasive and nonradioactive determination of microscopic lymph node tumor status by multispectral optoacoustic imaging (2015) (4)
- Rapid progression of a splenic aneurysm due to segmental arterial mediolysis: a rare cause of acute pancreatitis. (2013) (4)
- Panel sequencing melanomas. (2015) (4)
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib (2021) (4)
- Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. (2021) (4)
- Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) (4)
- Segmentally arranged seborrhoeic keratoses with impending atypia and squamous cell carcinoma in an elderly woman (2015) (4)
- Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment (2022) (4)
- Targeting mitosis-regulating genes in cisplatin-sensitive and -resistant melanoma cells: A live-cell RNAi screen displays differential nucleus-derived phenotypes. (2015) (4)
- The use of histamine in cancer immunotherapy. (2002) (4)
- The genetic landscape of clinical resistance to RAF inhibition in melanoma. (2013) (4)
- Intraventricular melanocytoma diagnosis confirmed by gene mutation profile (2018) (4)
- Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation–Induced DNA Damage and Melanoma Susceptibility (2021) (4)
- [Drug resistance of malignant melanoma. Mechanisms and possible modulation]. (1994) (4)
- Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis (2021) (4)
- Postsurgical Treatment of Split Skin Graft Donor Sites in Dermatological Departments (2018) (4)
- Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma. (2006) (4)
- A randomized trial of IFNα/IL-2 with or without CDDP in advanced melanoma: An EORTC melanoma cooperative group trial (1996) (4)
- Evaluation of a Deep Learning Approach to Differentiate Bowen’s Disease and Seborrheic Keratosis (2022) (4)
- Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting (2019) (3)
- Vaccination with Dendritic Cells - A Specific Immunomodulatory Approach for the Treatment of Malignant Melanoma (1997) (3)
- Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. (2017) (3)
- Reply to M. Perier-Muzet et al. (2014) (3)
- The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. (2020) (3)
- Merkelzellkarzinom (2019) (3)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (3)
- 1245PQuality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma (2017) (3)
- Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. (2023) (3)
- Efficacy Outcomes in the Phase 3 COMBI-AD Study of Adjuvant Dabrafenib Plus Trametinib vs Placebo in Patients with Stage III BRAFV600E/K-Mutant Melanoma (2018) (3)
- PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. (2022) (3)
- Palliativer Therapieansatz bei Fern-und Hirnmetastasen des malignen Melanoms mit Temozolomid und Hirnbestrahlung (2000) (3)
- Brain metastases of metastatic malignant melanoma: Response to DTIC and interferon-gamma (1993) (3)
- Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). (2016) (3)
- Adverse events (AEs) over time in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (Pbo) in the COMBI-AD trial. (2018) (3)
- Web-based mindfulness and skills-based distress reduction for patients with cancer: study protocol of the multicentre, randomised, controlled confirmatory intervention trial Reduct (2022) (3)
- Sensitivity of human melanoma cells in vitro to chemotherapy, interferons and combinations of both (1993) (3)
- Tumorimmunologische Strategien in der Dermatoonkologie (2003) (3)
- Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival (2022) (3)
- High-resolution three-dimensional imaging for precise staging in melanoma. (2021) (3)
- STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients (2014) (3)
- Garbe C, Hauschild A, Volkenandt M et al.Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma. Melanoma Res 17:393-399 (2008) (3)
- Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility (2020) (3)
- Adverse events of special interest in the phase 3 COLUMBUS study. (2018) (3)
- Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up (2020) (3)
- Systemic allergic contact dermatitis from intravenous piritramide (2010) (3)
- Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial (2017) (3)
- Effect of mTOR inhibitors on sorafenib-induced endoplasmic reticulum stress and apoptosis in melanoma cells. (2010) (3)
- Psoriasis im Kindes- und Jugendalter (2012) (3)
- Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma (2021) (3)
- 23 A prospective randomised multi-centre trial for the treatment of primary high-risk melanoma using s.c. interleukin-2 and interferon-alpha (1995) (3)
- Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL). (2015) (3)
- Klippel-Trénaunay-Syndrom – eine seltene Ursache eines chronischen Ulcus cruris (2010) (3)
- A new tyrosinase epitope recognized in the HLA-B*4002 context by CTL from melanoma patients (2009) (3)
- Juvenile Psoriasis – Versorgungssituation und Lebensqualität in Deutschland (2013) (3)
- Nebenwirkungen onkologischer Systemtherapien in der Dermatologie (2012) (3)
- Re: van Poppelen et al.: Genetic background of iris melanomas and iris melanocytic tumors of uncertain malignant potential (Ophthalmology. 2018;125:904-912). (2018) (3)
- Health-related quality of life in patients with fully resected BRAFV600 mutation-positive melanoma receiving adjuvant vemurafenib. (2019) (3)
- Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. (2019) (3)
- 277 Human mast cell and basophil cell lines produce interleukin 8 and 6 (1991) (3)
- Phase Ib/II study (SENSITIZE) assessing safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical outcome of domatinostat in combination with pembrolizumab in patients with advanced melanoma refractory/non-responding to prior checkpoint inhibitor therapy (2019) (2)
- MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. (2022) (2)
- Expression and functional activity of the IL-8 receptor by human mast cells (1994) (2)
- Meeting report: consensus from the first and second Global Workshops in Melanoma November 19–20, 2008 (2009) (2)
- Immunotherapy of Melanoma: A New Era (2011) (2)
- Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (2019) (2)
- NRAS-mutated melanoma patients have similar response rates to therapy with checkpoint inhibitors as other cohorts. (2017) (2)
- Comparison of adherent lymphokine-activated killer (a-lak) cells generated by IL-2 and IL-7 - cellular modifications induced by IL-7. (1995) (2)
- Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma (2022) (2)
- Vemurafenib treatment in patients with BRAF-mutated melanoma failing MEK inhibition with trametinib. (2014) (2)
- 1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 (2021) (2)
- Validating Automatic Concept-Based Explanations for AI-Based Digital Histopathology (2022) (2)
- Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). (2019) (2)
- Anticancer innovative therapy congress: Highlights from the 10th anniversary edition. (2021) (2)
- Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (2)
- Detergent fractionation with subsequent subtractive suppression hybridization as a tool for identifying genes coding for plasma membrane proteins (2009) (2)
- Development Process of Quality Indicators for the S3-Guideline Melanoma (2013) (2)
- Conference on cancer vaccines (2000) (2)
- Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity (2022) (2)
- Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study (2021) (2)
- Evaluation of the Melanoma Tumor Burden Score (MTBS) in a real-world setting. (2017) (2)
- Comparison of mutation profiles in primary melanomas and corresponding nodal naevi using next‐generation sequencing (2021) (2)
- Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial. (2021) (2)
- Kurzleitlinie: Malignes Melanom der Haut (2006) (2)
- Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma (2022) (2)
- Cytokines and Cytokine Gene Transfer in Cancer Treatment (1997) (2)
- Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i) (2022) (2)
- Melanocortin receptor 1 variants and melanoma risk – a study on two European populations (2008) (2)
- Angioplasmacellular Hyperplasia—A New Histopathologic Clue for Anogenital Herpes Simplex Recidivans in Immunocompromised Patients? (2014) (2)
- Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. (2020) (2)
- TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy (2022) (2)
- Introduction to Cutaneous Melanoma (2013) (2)
- Handbook of cutaneous melanoma (2013) (2)
- Estimate of long-term relapse-free survival (RFS) and analysis of baseline factors associated with RFS in the COMBI-AD trial. (2018) (2)
- Differential promoter activity in benign and malignant human cells of skin origin * (1995) (2)
- 1224PDAnalysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002 (2017) (2)
- High-resolution 3-D imaging for precise staging in malignant melanoma (2020) (2)
- [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group]. (1998) (2)
- Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) (2)
- 1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in melanoma (2020) (2)
- [Acute juvenile pityriasis rubra pilaris in a 2-year-old child]. (2004) (2)
- Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials (2019) (2)
- Treatment in metastatic melanoma-time to re-think. (2019) (2)
- Quality-of-Life (QoL) in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma (2017) (2)
- EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600–mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition. (2022) (2)
- Treatment in metastatic melanoma-time to re-think. (2019) (2)
- Allosteric and ATP-Competitive MEK-Inhibition in a Novel Spitzoid Melanoma Model with a RAF- and Phosphorylation-Independent Mutation (2021) (2)
- Cell Receptor NKG 2 D KillerExpression of ULBP 2 , a Stress-Induced Ligand of the Natural Tumor Suppressive MicroRNAs miR-34 a / c Control Cancer Cell (2012) (2)
- Genetic characterization of advanced conjunctival melanoma and response to systemic treatment. (2022) (2)
- [90-year-old male with a hyperkeratotic lichenoid skin eruption]. (2005) (2)
- [Information services for melanoma patients and awareness among those affected]. (2018) (2)
- Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. (2022) (2)
- Most Cited Authors... (2008) (2)
- The Janus-faced role of KDM5B heterogeneity in melanoma: differentiation as a situational driver of both growth arrest and drug-resistance (2020) (2)
- 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma (2021) (2)
- Salivary cortisol levels and anxiety in melanoma patients undergoing sentinel lymph node excision under local anesthesia versus general anesthesia: a prospective study (2020) (2)
- The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity (2022) (2)
- Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial. (2022) (2)
- PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. (2017) (2)
- 787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial (2022) (2)
- Human Mast Cells IL-8 Receptor Type CXCR 1 and CXCR 2 on Expression and Functional Activity of the (1998) (2)
- Placebo responses in patients with house dust mite allergy (2013) (2)
- B-type natriuretic peptides for the prediction of cardiovascular events and mortality in patients living with HIV: Results from the HIV-HEART study. (2019) (2)
- A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM). (2018) (2)
- Sebaceous tumours: more than skin deep (2017) (2)
- Impact of Prior Lines of Systemic Therapy (PST) on the Efficacy Of Cemiplimab, a Human Monoclonal Anti–PD-1, in Patients (PTS) with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) (2019) (2)
- Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes. (2011) (2)
- Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG) (2020) (2)
- Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients (2005) (2)
- Determination of granulocyte/macrophage-colony-stimulating factor secretion by human melanoma cells and its effects on human melanoma cell proliferation (2005) (2)
- EGFR-Inhibitoren und Multityrosinkinaseinhibitoren (2011) (2)
- Update der S3-Leitlinie zum malignen Melanom (2017) (2)
- Medikamentöse Systemtherapie des Melanoms (2014) (2)
- Prognose des primären und metastasierten malignen Melanoms : Abschliessende Auswertung des geschlossenen Patientenkollektivs an der Hautklinik des Virchow Klinikums, Berlin, von 1981 bis 1995 (1996) (2)
- Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms (2012) (2)
- Informationssuche und Nutzung von Informationsquellen durch Melanompatienten deutscher Hautkrebszentren (2018) (2)
- Leitlinienbasierte Qualitätsindikatoren und Zertifizierung als Grundlage für die Qualitätssicherung der Versorgung von Patienten mit Melanom (2014) (2)
- Ultraschall in der Therapie chronischer Wunden (2009) (2)
- Interleukin-7 in der Dermatologie Molekulare, immunologische und präklinische Aspekte (1995) (2)
- Abstract 1977: The protein phosphatase 2 subunit PR48 is a novel melanoma tumor suppressor gene. (2013) (1)
- Tumor necrosis factor alpha blockade prevents immune checkpoint inhibitor therapy-related cardiotoxicity (2020) (1)
- Laser-Assisted Delivery Of Cold Atmospheric Plasma In Unresectable Cutaneous Metastasis In Melanoma Patients (2018) (1)
- 767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY (2008) (1)
- Predictors of quality of life in melanoma patients 4 years after diagnosis: Results of a nationwide cohort study in Germany (2018) (1)
- Informations‐ und Hilfsangebote für Melanompatienten: Präferenzielle Unterschiede zwischen Patienten und Ärzten (2019) (1)
- Preclinical and clinical assessment of immune checkpoint inhibitor-associated left ventricular dysfunction (2020) (1)
- Overall survival of patients with chemotherapy-naive advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials (2014) (1)
- Best supportive care in combination with polychemotherapy versus best supportive care alone as second-line therapy in stage IV metastatic melanoma (DeCOG MM-PAL 8) (2007) (1)
- Tumorspezifische Therapieansätze in der Onkologie (2001) (1)
- Abstract B16: NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with advanced NRAS-mutant melanoma who are untreated or have progressed on or after immunotherapy (2015) (1)
- Health-related quality of life (HRQoL) with pembrolizumab (pembro) in resected high-risk stage II melanoma in the phase 3 KEYNOTE-716 study. (2022) (1)
- Medikamentöse Therapie des metastasierten Melanoms im Rahmen prospektiv-randomisierter Studien (2004) (1)
- 1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL. (2014) (1)
- Pilomatrixkarzinom mit lymphogener Metastasierung - ein Fallbericht (2004) (1)
- Cancer Patients’ Age-Related Benefits from Mobile Neurofeedback-Therapy in Quality of Life and Self-efficacy: A Clinical Waitlist Control Study (2022) (1)
- Immune checkpoint blockade for organ-transplant recipients with cancer: A review. (2022) (1)
- EUMelaReg: A European platform for outcome research on real world treatment data of patients with advanced melanoma. (2018) (1)
- Diagnosis and Follow-up of Melanoma - what will change with the new S3 Guideline? (2013) (1)
- 819P Efficacy of dabrafenib (D) trametinib (T) plus spartalizumab (S) by baseline site of metastases in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: Post hoc analysis of phase III COMBI-i trial (2022) (1)
- Obesity is associated with altered tumor metabolism in metastatic melanoma. (2022) (1)
- Hat die Vakzination von Tumorpatienten eine Zukunft in der klinischen Onkologie? (2002) (1)
- Framingham risk score and cardiovascular risk profiles in HIV+ patients and HIV- controls differ by sex (2013) (1)
- Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG (2022) (1)
- Prospective comparative study of two rehabilitation schemes in 2354 patients with malignant melanoma (2011) (1)
- Rational Development of Peptide Vaccination in Clinical Oncology. Concerning Jäger E, et al.: Peptide vaccination in clinical oncology. Onkologie 2000;23:410–415. (2001) (1)
- Multispectral optoacoustic tomography to differentiate between lymph node metastases and coronavirus‐19 vaccine‐associated lymphadenopathy (2023) (1)
- Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]. (2018) (1)
- Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data. (2019) (1)
- Differential in fl uence of vemurafenib and dabrafenib on patients ’ lymphocytes despite similar clinical ef fi cacy in melanoma (2014) (1)
- Sexualverhalten, STIs und HIV‐Übertragungsrisiken bei HIV‐positiven MSM – Ansätze für die ärztliche Präventionsarbeit (2017) (1)
- 2416PD1-blocking immune checkpoint inhibitor therapy for malignant melanoma induces left ventricular dysfunction (2019) (1)
- Elimination of Dendritic Cells in Cancer (2009) (1)
- Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis (2020) (1)
- Immuntherapie des Melanoms (2012) (1)
- Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors (2022) (1)
- Merkel-Zell-Karzinom (2021) (1)
- Alternative Strategien in der Therapie des malignen Melanoms (1997) (1)
- [Perianal ulcerations caused by potassium permanganate bath]. (2010) (1)
- Metastatic recurrence of 17‐year relapse‐free melanoma during anti‐TNFa therapy (2017) (1)
- Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C). (2013) (1)
- Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity (2022) (1)
- Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). (2019) (1)
- Abstract 4714: Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. (2013) (1)
- FC10 Sorafenib and pegylated interferon alpha 2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial (2010) (1)
- Chemotherapie des fortgeschrittenen malignen Melanoms - Ein Überblick anhand der Ergebnisse randomisierter kontrollierter klinischer Studien - (2002) (1)
- Entscheidungsfindung für die klinische Praxis: Aktuelle Konzepte und Behandlungsalgorithmen mit Immun-Checkpoint-Inhibitoren beim Melanom (2016) (1)
- Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma (2016) (1)
- miR-101 is dysregulated in malignant melanoma and targets MITF (2010) (1)
- Intermittent intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III malignant melanoma: Pooled analysis of two randomized phase III trials (NCT00226408 and ISRCTN75125874) with 980 patients. (2013) (1)
- ‘PEG meets Liposome’ – zwei Technologien führen zu einer Substanz mit neuem Profil (2001) (1)
- 25 Update of EORTC melanoma trials. Final results of the EORTC melanoma group trials: EORTC 18951 in stage IV and EORTC 18952 in stage IIB–III (2004) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial. (2014) (1)
- 871P Predictive role of neutrophil-lymphocyte ratio (NLR) in patients (pts) with metastatic melanoma: A post hoc exploratory analysis from phase III COMBI-i trial (2022) (1)
- Biology of Human Tumors Circulating CD 4 þ T Cells That Produce IL 4 or IL 17 When Stimulated by MelanA but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma (2014) (1)
- Chemoresistance in Cancer Cells (2004) (1)
- Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma (2015) (1)
- Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma (2022) (1)
- PHASE I TRIAL OF ADJUVANT VACCINATION WITH TYROSINASE PEPTIDES AND GM-CSF IN MELANOMA (1999) (1)
- 90jähriger Patient mit hyperkeratotisch‐lichenoiden Hautveränderungen (2005) (1)
- Reply to E. Hindié and K.R. Hess. (2019) (1)
- Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype (2022) (1)
- PO-332 Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E-inhibition in melanoma (2018) (1)
- Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. (2022) (1)
- Mutational and immune gene expression profiling at relapse in patients (pts) treated with adjuvant dabrafenib plus trametinib (D + T) or placebo (pbo) in the COMBI-AD trial. (2018) (1)
- Impact of HLA-A2 Status on Ipilimumab Efficacy and Safety: Pooled Data from Four Phase II Trials in Advanced Melanoma (2010) (1)
- NEMO: A Phase 3 Trial of Binimetinib (MEK162) Versus Dacarbazine in Patients With Advanced NRAS-Mutant Melanoma Who Are Untreated or Have Progressed After Immunotherapy (2014) (1)
- Diagnostische Anstrengungen in der Melanomnachsorge : welche werden belohnt ? (1999) (1)
- Genetc and morphologic features for melanoma classification: implications for clinical trials (2010) (1)
- Neurofibromatose Typ 1 - Klinik und Genetik (Synonym: Morbus von Recklinghausen) (2004) (1)
- P35 Status quo of the S3 guideline ‘Diagnosis, treatment and follow-up of melanoma’ in Germany (2010) (1)
- UV-Schutz-Bündnis in Deutschland – Zweck und Ziele (2022) (1)
- Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches (2008) (1)
- A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma (2015) (1)
- The price of tumor control (2013) (1)
- Advancements in melanoma cancer metastasis models (2022) (1)
- 1192PCytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis (2017) (1)
- One Website to Gather them All: Usability Testing of the New German SKin Cancer INFOrmation (SKINFO) Website-A Mixed-methods Approach. (2022) (1)
- Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis. (2021) (1)
- Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. (2018) (1)
- Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy (2021) (1)
- The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition (2022) (1)
- Fatal swelling of the groin – Clear cell sarcoma: a rare but important differential diagnosis to malignant melanoma (2020) (1)
- Association between the B-RAF/N-RAS mutations, the CDKN2A alterations and the MC1R variants in melanoma (2006) (1)
- Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). (2019) (1)
- Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma (2018) (1)
- 1066P Extended-dose cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Primary analysis of phase II results (2021) (1)
- UV-Schutz-Bündnis in Deutschland – Zeitstrahl der inhaltlichen Entwicklung (2022) (1)
- Immuntherapie des Melanoms (2012) (1)
- Activation of p 38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to BecomeTolerogenic in Ret Transgenic Mice Spontaneously DevelopingMelanoma (2009) (1)
- [Gene therapy in malignant melanoma. Interview with D. Schadendorf]. (1996) (1)
- Informationsangebote für Melanompatienten und ihre Bekanntheit unter Betroffenen (2018) (1)
- Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (2022) (1)
- Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence. (2022) (1)
- [Early detection for prevention of malignant melanoma in Berlin]. (1992) (1)
- Reply to the letter to the editor: 'Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images'. (2020) (1)
- Effektive Lymphknotendissektion bei primärem malignen Melanom Hautarzt (1996) 47:29–34 (1996) (1)
- Abstract CT120: A randomized, open-label, open-platform, Phase II study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATforM) (2019) (1)
- Active remodeling of capillary endothelium via cancer cell-derived MMP9 promotes metastatic brain colonization. (2023) (1)
- Adjuvant pegylated interferon α-2b therapy for melanoma. (2010) (1)
- Impact of a functional polymorphism in the IL12B promoter region on survival in patients with malignant melanoma. (2016) (1)
- Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems (2021) (1)
- Enforced polarization of melanoma cells towards a JARID1B-high phenotype exhausts tumour fitness (2017) (1)
- Pegylated liposomal doxorubicin plus paclitaxel as an individualized chemosensitivity-directed treatment in advanced metastatic melanoma (2007) (0)
- Authors' reply (2000) (0)
- Abstract 3514: A genetic-metabolic circuit of liver-specific metastatic organotropism (2023) (0)
- Cancer Therapy : Clinical Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermato fi brosarcoma Protuberans : AMulticenter Phase II DeCOG Trial with Long-term Follow-up (2014) (0)
- Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population. (2023) (0)
- Checkpointinhibitoren@@@Checkpoint inhibitors (2017) (0)
- Neuropilin-1 mediates infiltration of regulatory T cells into tumors favoring immune escape (P2063) (2013) (0)
- Adjuvant dabrafenib plus trametinib (D + T) versus placebo in patients with resected stage III BRAFV600-mutant melanoma: Updated 5-year distant metastases-free survival (DMFS) analysis of COMBI-AD. (2022) (0)
- Neo-adjuvant Therapy of Dermatofibrosarcoma protuberans with Imatinib: A multicenter Phase II Study of the ADO (2013) (0)
- Interferon T downregulates EGF-R expression on human melanoma cells—determination of the relevance of EGF and EGF-R on proliferation of human melanoma cells (1993) (0)
- Identifizierung von spezifischen Plasmamembranproteinen des kutanen T-Zell Lymphoms (2004) (0)
- Computed tomography-guided biopsy of radiologically unclear lesions in advanced skin cancer: A retrospective analysis of 47 cases. (2021) (0)
- Prognostic and predictive value of metformin in the EORTC 1325/KEYNOTE- 054 phase III trial of pembrolizumab vs placebo in resected high-risk stage III melanoma (2023) (0)
- Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2021) (0)
- 4. Interdisziplinärer Kongress „Quality of Cancer Care“ (QoCC 2019) (2019) (0)
- Nucleic acid, the protein of the CTAGE family encodes a whose use and preparation (2000) (0)
- Chemotherapy of metastatic malignant melanoma directed by in vitro sensitivity testing: 164 (1993) (0)
- Fear of progression in patients with low-risk malignant melanoma. (2017) (0)
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2020) (0)
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma (2019) (0)
- Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. (2022) (0)
- Revised guidelines for authors of gene mapping reports (2000) (0)
- Prognostic factors in the surgical treatment of melanoma lung metastasis: a high-volume single center experience (2017) (0)
- Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 Groups 1, 2, and 3 (2023) (0)
- Reply to E. Hindié. (2021) (0)
- Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells (2010) (0)
- The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma (2023) (0)
- Melanoma and Immunother apy (2009) (0)
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade (2019) (0)
- Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma (2023) (0)
- Corrigendum to Letter to the Editor: Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT (2011) (0)
- Metastatic pigmented epithelioid melanocytoma in a 7‐year‐old female (2021) (0)
- Vorwort (2013) (0)
- Vorwort (2012) (0)
- 817P Nivolumab (NIVO) + relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047 (2022) (0)
- Update (1972) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI). (2015) (0)
- Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. (2012) (0)
- Activity of viral promotors in cultered human skin cells (1993) (0)
- Metabolic heterogeneity confers differences in melanoma metastatic potential (2019) (0)
- COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates (2022) (0)
- Clinical and pathological characteristics of familial melanoma with germline TERT promoter variants (2022) (0)
- Band 24, Heft 2, April 2001 (2001) (0)
- Vorwort (2001) (0)
- Dr. Dirk Schadendorf (2017) (0)
- The European Searchable Tumour Cell and Databank, ESTDAB, as a tool for research in cancer immunology (2004) (0)
- Nodöse Scabies: Hypersensitivitätsreaktion oder Infektion? (2011) (0)
- Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study. (2021) (0)
- Genetic and Dendritic Cell Vaccination as a Novel Therapy for Melanoma (2001) (0)
- An essential interdisciplinary partnership of Nuclear Medicine and Dermato-Oncology: Advantages of preoperative SPECT/CT detecting sentinel lymph nodes in malignant melanoma (2011) (0)
- Retraction Note to: cGMP-phosphodiesterase 6, transducin and Wnt5a/Frizzled-2-signaling control cGMP and Ca2+ homeostasis in melanoma cells (2020) (0)
- Optimale Systemtherapie beim kutanen Melanom (2017) (0)
- Association of PD-L1 expression in melanoma with response and prognosis to ipilimumab. (2015) (0)
- Multicenter study on prognostic factors in 692 patients with brain metastases of malignant melanoma. (2009) (0)
- Outcome on 560 metastatic melanoma (MM) patients treated with pembrolizumab during the German Expanded Access Program (EAP) (2016) (0)
- Treatment of Distant and Irresectable Metastatic Disease (2013) (0)
- Gene Therapy: A New Perspective for the Treatment of Malignant Melanoma (1997) (0)
- 1075P Regression tree analysis to identify factors associated with relapse-free survival (RFS) in patients with resected stage III BRAF V600E/K–mutant melanoma (2021) (0)
- Photoreceptor proteins as cancer-retina antigens in melanoma (2006) (0)
- 1091TiP STARBOARD: Randomized phase III study of encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma (2021) (0)
- Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis. (2023) (0)
- Diagnosis, Staging, and Follow-up (2013) (0)
- 136-78: PROLONGATION OF THE QTc INTERVAL IN HIV INFECTED INDIVIDUALS COMPARED TO THE GENERAL POPULATION (2016) (0)
- 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO (2020) (0)
- 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma (2022) (0)
- EORTC Melanoma Group achievements (2012) (0)
- [State-of-the-art pharmacotherapy of malignant melanoma]. (2011) (0)
- Apoptosis in Melanoma Approaches to Therapy (0)
- Subject Index Vol. 26, 2003 (2003) (0)
- Database for queries of melanoma cohorts with molecular and clinical data (2022) (0)
- Subject Index Vol. 87, 1999 (2000) (0)
- B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma. (2023) (0)
- PO-493 ctDNA profiles of metastatic melanoma patients under therapy (2018) (0)
- Keyhole Limpet Hemocyanin (KLH)-pulsed dendritic cells induce longterm Th1-type immune response in patients with metastatic melanoma (1998) (0)
- Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. (2023) (0)
- Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma (2022) (0)
- 7503-114079-1-Sp (2016) (0)
- Response. (2015) (0)
- P44. Mouse models of spontaneous melanoma as a tool for development of new immunotherapies of human melanoma (2006) (0)
- Reply to M. Horiguchi et al. (2018) (0)
- 3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective (2015) (0)
- Band 25, Supplement 1, März 2002 (2002) (0)
- Immunization strategies in advanced melanoma (1999) (0)
- Epitheloides malignes Schwannom (EMS) der Haut : Differentialdiagnose und Fallbericht (1998) (0)
- Consultant Oral Session Abstracts (2018) (0)
- 1226PDFive-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma (2017) (0)
- Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial (2018) (0)
- Acanthosis nigricans (2010) (0)
- Title Page / Contents / Imprint (2014) (0)
- PO-399 Tumour CDKN2A loss predisposes to immunotherapy resistance (2018) (0)
- Melanoma Group achievements (2012) (0)
- Association of single-nucleotide polymorphisms in DNA repair genes with progression and survival of primary cutaneous melanoma patients (2008) (0)
- Quality, Readability, and Understandability of German Booklets Addressing Melanoma Patients (2018) (0)
- 784O Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial (2022) (0)
- Apoptosis in BRAFV600E Melanoma Cells Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated ` (2013) (0)
- Melanoma vaccines. (2000) (0)
- Eine Übersicht über Therapiefortschritte in den letzten 50 Jahren beim Metastasierten Melanom (2016) (0)
- Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib. (2014) (0)
- Hautkrebsforschung reloaded: Paradigmenwechsel in der Dermatoonkologie (2013) (0)
- [Tumor-specific therapy strategies in oncology]. (2001) (0)
- Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) (0)
- S3-Guideline Diagnosis, Treatment and Care of Melanomas: Methodological Foundations (2010) (0)
- 606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology (2022) (0)
- Preoperative serum lactate dehydrogenase, but not BRAF or NRAS mutational status are prognostic factors after pulmonary melanoma metastasectomy (2022) (0)
- A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma (2016) (0)
- Neurofeedback Treatment Affects Affective Symptoms, But Not Perceived Cognitive Impairment in Cancer Patients: Results of an Explorative Randomized Controlled Trial (2023) (0)
- Clinical Perspectives TM Highlights from the Perspectives in Melanoma XII Conference (2009) (0)
- Abstract 4835: Gonosome-linked expression of PPP2R3B in cutaneous melanoma correlates with distant metastasis free survival (2011) (0)
- PO-263 Epigenetic modulation of cell metabolism and its effects on cell survival in melanoma (2018) (0)
- 14. Alkylating Agents (2013) (0)
- Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD‐1 inhibitors (2021) (0)
- Specific cellular immune responses against NY-ESO-1 are associated with favorable survival of stage IV melanoma patients (2011) (0)
- Mykotische und bakterielle Infektionen (2010) (0)
- 8th Annual Meeting of the German Working Group for Gene Therapy (DAG-GT e.V.) (2014) (0)
- Abstract 6403: Molecular correlates of clinical benefit from circulating tumor DNA (ctDNA): Analysis of the COLUMBUS study (2022) (0)
- Avelumab Induced Severe Disabling Myositis in A Patient with Merkel Cell Carcinoma (2020) (0)
- 308 Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for melanoma (2020) (0)
- Abstract 2547: Peripheral immune signatures and survival in stage IV melanoma (2014) (0)
- Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. (2020) (0)
- The "Intimarzt" (intimate doctor) Model Project: Anonymous Remote Diagnosis of Sexually Transmitted Diseases. (2023) (0)
- Model soups improve performance of dermoscopic skin cancer classifiers. (2022) (0)
- Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure (2017) (0)
- Prospective center-randomized trial of melanoma surveillance in 3,833 patients: An analysis of the early detection of recurrences (2007) (0)
- Distinct immunogenomic properties of melanomas with stable disease as best response to immune checkpoint blockade (ICB). (2019) (0)
- Abstract 5056: A glimpse into the somatic mutation landscape of melanoma through exome sequencing of 121 tumor-normal pairs (2012) (0)
- 608 Predicting primary resistance and exploring mechanisms in patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) (2022) (0)
- 30 years German Dermatologic Cooperative Oncology Group (DeCOG) (2021) (0)
- Contents Vol. 26, 2003 (2003) (0)
- [Working Group on Dermatological Oncology -- a dermatological success story]. (2014) (0)
- Comprar Handbook Of Cutaneous Melanoma. A Guide To Diagnosis And Treatment | Dirk Schadendorf | 9781908517975 | Springer (2013) (0)
- Immune escape mechanisms in melanoma patients vaccinated with peptide pulsed dendritic cells (1998) (0)
- The GERMELATOX DeCOG-trial: German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment. (2014) (0)
- Chapter 17 Immunotherapy of Melanoma: A New Era (2011) (0)
- Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours (2020) (0)
- Vorwort (2016) (0)
- Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial, (2023) (0)
- PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma (2020) (0)
- 3351 Concordance of BRAF V600E mutation status in metastatic melanoma patients by comparison of results from circulating tumor DNA and tissue-based testing (2015) (0)
- Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS (2022) (0)
- Ein neues 10mer Epitop aus dem TRP2 (Tyrosinase related protein 2) Differenzierungsantigen des Melanoms aktiviert CD8+ T-Lymphocyten aus HLA-A1+, HLA-A2- und HLA-A1-, HLA-A2+ Donoren (2003) (0)
- Qualitative Einschätzung von Informationsbroschüren für Melanom-Patiente (2017) (0)
- C URRENT OPINION New developments in biomarkers for melanoma (2013) (0)
- Facial Variant of Eruptive Vellus Hair Cysts: A Case Report and Brief Review of the Literature (2010) (0)
- Pegylated Interferons in the Adjuvant Treatment of Melanoma (2009) (0)
- [Cutaneous angiosarcoma clinically presenting as Quincke's edema]. (2021) (0)
- Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter DeCOG study on 637 patients from the prospective skin cancer registry ADOREG (2023) (0)
- Treatment of Primary Tumor and Locoregional Disease (2013) (0)
- New markers for the diagnosis and therapy of tumors (2000) (0)
- CEACAM1: a novel target of MITF in malignant melanoma (2016) (0)
- Association of critical losses in X chromosome with melanoma progression: An EORTC Melanoma group study. (2008) (0)
- Abstract 5254: Sentinel lymph node detection and in vivo/ex vivo assessment of melanin distribution by means of multispectral optoacoustic tomography (MSOT) in patients with malignant melanoma (2015) (0)
- Randomized P hase I II S tudy o f T emozolomide V ersus Dacarbazine i n t he T reatment o f P atients W ith A dvanced Metastatic M alignant M elanoma (2000) (0)
- 3D data related to: Identification and quantification of hidden melanoma metastases in human sentinel lymph nodes using light sheet fluorescence microscopy (2020) (0)
- Fluoreszenz‐Markierung mittels Indocyanin‐Grün bei der Sentinel‐Lymphknoten‐Exstirpation in der Dermatoonkologie (2012) (0)
- Reply to the letters to the editor 'Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma' by Diwakar et al. (2015) (0)
- C URRENT OPINION Brain metastasis: opportunity for drug development? (2012) (0)
- 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) (2017) (0)
- [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma]. (2011) (0)
- Fortschritte bei Systemtherapie verbessern Prognose (2021) (0)
- Primäres amelanotisches Harnblasenmelanom -eine seltene Ursache für eine Hämaturie (2000) (0)
- Gegen den Hautkrebs: Forschung zur Überwindung immuntherapeutischer Hürden beim malignen Melanom (2012) (0)
- Oberrheinische Arbeitsgemeinschaft für Onkologie (OAO/GTOR/AOR) / Deutsche Krebsgesellschaft e.V. (2003) (0)
- Innovative Konzepte zur Immunintervention bei Hauttumoren: Vakzinierung mit Tumorantigen beladenen dendritischen Zellen (2000) (0)
- A randomised phase 2 study of Paclitaxel with or without Trametinib or Pazopanib in advanced wild type BRAF melanoma (2017) (0)
- Phase II-Studie zur Vakzinierung von Melanompatienten mit Tyrosinase-Peptiden und GM-CSF (2000) (0)
- Die neue S3-Leitlinie „Melanom“ (2013) (0)
- Isolierte zerebrale Suszeptibilitätsartefakte bei Patienten mit malignem Melanom: Metastase oder nicht? (2012) (0)
- Immer eine morphologische Beschreibung beifügen (2018) (0)
- 1. Wertheimer Onkologie-Gespräch «Das nicht-kleinzellige Bronchialkarzinom (NSCLC) mit Taxotere® frühzeitig wirksam behandeln» (2003) (0)
- Vorteile einer präoperativen SPECT/CT in der Detektion von Sentinel-Lymphknoten beim malignen Melanom Eine retrospektive Analyse von 406 Patienten (2011) (0)
- Laudatio anlässlich der Emeritierung von Prof. Dr. Claus Garbe (Tübingen) (2019) (0)
- Vakzination mit dendritischen Zellen im Vergleich zu DTIC – Ergebnisse einer Phase-III-Studie (2004) (0)
- Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten (2013) (0)
- Interleukine und Wachstumsregulation von Melanomzellen (2004) (0)
- Das Serumproteomprofil als prognostischer Index beim malignen Melanom (2004) (0)
- Mikro- und Makrodeletionen chromosomaler Sequenzen führen zum Verlust der HLA Klasse I Expression auf Tumorzellen (2004) (0)
- Intraoperative use of LIGHTVISION: a novel fluorescence navigation system using indocyanine green for sentinel lymph node biopsy in skin cancer patients (2018) (0)
- Aftercare and Follow-up in malignant Melanoma (2013) (0)
- Prognostische Genexpressionstests beim Melanom auf dem Weg in die Routine (2020) (0)
- Kardiovaskuläre Risikofaktoren bei Psoriasis - Ergebnisse aus der Heinz Nixdorf Recall Studie (2011) (0)
- Neue Tumor-Antigene im Zusammenhang mit Melanom-assoziierter Retinopathie (2004) (0)
- Prospektive vergleichende Untersuchung zweier Nachsorgeschemata bei 2354 Patienten mit malignem Melanom (2011) (0)
- Seltene Tumoren des Integuments (1999) (0)
- Therapie des malignen Melanoms (2015) (0)
- Pyruvat-Kinase Typ M2: Ein neuer prognostischer Marker beim malignen Melanom (2003) (0)
- Immunonkologie im Fokus (2014) (0)
- Hautkrebs: 3. Interdisziplinres Expertenforum, Hamburg, Dezember 2012 (2013) (0)
- Bräunungscremes und Bräunungsbeschleuniger - Übersicht, Risiken, praktische Tipps (2005) (0)
- Langerhans-Zell-Histiozytose mit Hautveränderungen im Erwachsenenalter (2000) (0)
- Translationale ADO-Registerstudie TRIM-ADJUVANT beim Melanom (2020) (0)
- Zertifizierte Fortbildung (2007) (0)
- Malignes Melanom: Optionen für Patienten im fortgeschrittenen Stadium (2018) (0)
- Vakzinationstherapie beim Melanom (2000) (0)
- Klinische Pharmakologie (2011) (0)
- Analyse der humoralen Immunantwort gegen Tumorantigene mittels Serum-Antikörper Detektions Arrays (2004) (0)
- Melanome der Atemwege und des Gastrointestinaltrakts (2006) (0)
- Freie Vorträge (2015) (0)
- Limitierte Wirkung von Anti-PD-1 bei fortgeschrittenen Hauttumoren von Patienten mit hämatoonkologischer Grunderkrankung: eine retrospektive multizentrische Studie der ADO (2019) (0)
- Title Pages / 1. Interdisziplinäres Expertenforum Hautkrebs / Table of Contents / Teilnehmerverzeichnis (2011) (0)
- Sachwortverzeichnis Band 26, 2003 (2003) (0)
- Band 25, Heft 1, Februar 2002 (2002) (0)
- Das anorektale maligne Melanom (2008) (0)
- Früherkennung von Hauttumoren (2003) (0)
- Interleukin-2 und Checkpoint-Inhibition als erfolgreiche Therapiesequenz beim metastasierten Melanom: Fallbericht und retrospektive Analyse an 52 Patienten (2017) (0)
- Quantensprung durch zielgerichtete und Immuntherapie beim Melanom (2021) (0)
- «Optimierung der palliativen Therapie gastrointestinaler Tumoren» (2003) (0)
- Komplette Remission kutaner Satelliten- und in-transit Metastasen eines malignen Melanoms nach isolierter hyperthermer Extremitätenperfusion und topischer Imiquimodbehandlung (2003) (0)
- Lichen aureus : eine seltene Form der Pigmentpurpura (1993) (0)
- Kapazität der onkologischen Versorgung in deutschen onkologischen Spitzenzentren während der ersten 2 Jahre der COVID-19-Pandemie (2022) (0)
- O2-Aufnahmekapazitätmessung chronischer Ulcera nach topischer Hämoglobinapplikation mittels photooptoakustischer Tomografie -Initiale Ergebnisse einer prospektiven Studie- (2015) (0)
- First-line-Therapie beim inoperablen oder metastasierten Melanom (2020) (0)
- Hautkrebs: 1. Interdisziplinres Expertenforum, Hamburg, Dezember 2010 (2011) (0)
- Onkokardiologie: Neue Herausforderungen, neue Möglichkeiten./ Oncocardiology: new challenges, new opportunities. (2020) (0)
- Immuntherapien bei soliden Tumoren: Auf dem Weg zum Standard beim Melanom (2015) (0)
- 30 Jahre Arbeitsgemeinschaft Dermatologische Onkologie (ADO) (2021) (0)
- Update zum klinischen Einsatz von Inhibitoren mutierter Phosphokinasen beim Melanom (2017) (0)
- «Sicherheit für die Zukunft – Pathogeninaktivierung von Thrombozytenkonzentraten», Symposium im Rahmen des 36. Jahreskongresses der Deutschen Gesellschaft für Transfusionsmedizin und Immunhämatologie e.V., Innsbruck, 18. September 2003 (2003) (0)
- Manifestation einer systemischen Sklerodermie unter Therapie mit pegyliertem Interferon alpha bei metastasiertem Melanom (2004) (0)
- Kosten und Nutzen der Ausbreitungsdiagnostik beim Melanom (2006) (0)
- Primäre extrakutane maligne Melanome: Ein Überblick unter besonderer Berücksichtigung der Therapie (1998) (0)
- Moderne Pharmakotherapie des malignen Melanoms (2011) (0)
- Tödliche Schwellung der Leiste – Klarzellsarkom: eine seltene, aber wichtige Differenzialdiagnose zum malignen Melanom (2020) (0)
- [Working group of the Dermatologic Oncology]. (2009) (0)
- Title Pages / 2. Interdisziplinäres Expertenforum Hautkrebs / Table of Contents / Teilnehmerverzeichnis (2012) (0)
- Title Page / Impressum / Inhalt (2015) (0)
- Behandlungsalgorithmus bei Patienten mit malignem Melanom (2014) (0)
- Immunonkologie «Coming of Age» - die nächste Generation der Immun-Checkpoint-Inhibitoren (2014) (0)
- Characterisation and outcome of RAC1 mutated melanoma. (2023) (0)
- Emerging Therapies and Combination Approaches (2013) (0)
- Diagnostik und Therapie von gastrointestinalen Stromatumoren (GIST) (2015) (0)
- Somatische Gentherapie beim malignen Melanom (1997) (0)
- Tumortherapie - eine interdisziplinre Aufgabe: Herbstsymposium des Onkologischen Arbeitskreises Mannheim / Abschiedssymposium fr Prof. Dr. Wolfgang Queisser, Mannheim, September 2001 (2001) (0)
- Special · Krebskongress 2004: Termine (2003) (0)
- Seltene melanozytäre Tumoren (2006) (0)
- Palliative Therapie des malignen Melanoms im Stadium IV (2009) (0)
- Therapie mit Epoetin beta: Sicher und effektiv in der Prävention und Behandlung der tumorinduzierten Anämie (2003) (0)
- Neue Arzneimittel lassen hoffen (2018) (0)
- Mastozytosen ± Diagnostik, Klassifikation, Therapie, aktuelle pathophysiologische Ansätze (2005) (0)
- Inhalt Band 26, 2003 (2003) (0)
- Behandlung von Melanomen der Schleimhäute und Meningen (2006) (0)
- Abstract 2487: Distinct venous brain vessels provide structures for T lymphocyte recruitment to brain tumors in mouse models of intracranial melanoma (2022) (0)
- Das Wichtigste für die Praxis (2013) (0)
- Hautkrebs: 2. Interdisziplinres Expertenforum, Hamburg, Dezember 2011 (2012) (0)
- Einsatzmöglichkeiten in der klinischen Routinediagnostik (2016) (0)
- Experimentelle Therapie des Melanoms (2001) (0)
- Vakzinierungstrategien mit Hilfe der Gentherapie (2006) (0)
- CME Zertifizierte Fortbildung (2016) (0)
- Arbeitsgemeinschaft Dermatologische Onkologie – eine dermatologische Erfolgsgeschichte (2014) (0)
- Blockade von Immuncheckpoints (2016) (0)
- Aktuelle Therapiestudien beim Merkel-Zell-Karzinom (2020) (0)
- Qualitätsmanagement und Zertifizierung in der Onkologie. Bericht vom DGHO-Symposium anlässlich der DGHO-Jahrestagung am 30.09.2001 in Mannheim (2002) (0)
- Response to comment - Molecular pathology as a diagnostic aid in difficult to classify melanocytic tumours with spitzoid morphology. (2021) (0)
- Maligne Hauttumoren: Immunologische Checkpoint-Kontrolle (2013) (0)
- Abstract 571: Meta-analysis of genomic predictors of response to immune checkpoint therapy in metastatic melanoma (2017) (0)
- 836P Outcome of PD-1 inhibitor therapy of advanced melanoma patients according to demographic factors in a real-world setting across Europe (2022) (0)
- Abstract 5528: The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene (2017) (0)
- Liebe Leserinnen und Leser (2016) (0)
- [Interleukin 7 in dermatology. Molecular, immunologic and preclinical aspects]. (1995) (0)
- Ex-vivo sensitivity-directed combination chemotherapy compared to DTIC monochemotherapy in chemo-naive advanced metastastic melanoma (ChemoSensMM): A multicenter randomized phase-3 DeCOG trial. (2015) (0)
- An animal model of cutaneous cyst development enables the identification of three QTLs including the homologue of a human locus (TRICY1). (2019) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- Contents Vol. 87, 1999 (2000) (0)
- Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts (2018) (0)
- 1122P Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases (2020) (0)
- Predictors of responses to immune checkpoint blockade in advanced melanoma (2017) (0)
- HIV‐infection during treatment of a chronic hepatitis B virus infection: implications for PrEP? (2012) (0)
- XXXII. Annual Meeting of the ADF (2005) (0)
- 102 INVITED Current clinical experience with melanoma vaccines: peptides, proteins and dendritic cells (2007) (0)
- Deep Learning Assisted Diagnosis of Onychomycosis on Whole-Slide Images (2022) (0)
- Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
- [Obituary for Prof. Dr. med. Christiane Voit (Berlin)]. (2015) (0)
- Eine nicht-interventionelle, multi-zentrische, prospektive Studie zur kombinierten Behandlung von fortgeschrittenem Melanom mit Dabrafenib und Trametinib im praktischen All-tag ("real-world setting"): COMBI-r (2017) (0)
- AnalysisofDermatologic Events inVemurafenib-TreatedPatients WithMelanoma (2013) (0)
- Immunological Strategies to Fight Skin Cancer (2004) (0)
- 1079P Comparison of effectiveness and safety of nivolumab monotherapy or in combination therapy with ipilimumab in therapy-naïve and pretreated patients with advanced melanoma within the German noninterventional study NICO (2021) (0)
- Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma (2021) (0)
- [Forward: anti-tumor immunity and tumor immunology]. (2014) (0)
- Effects of various synthetic retinoids on proliferation and melanogenesis towards human melanoma cells in vitro (1993) (0)
- Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. (2021) (0)
- Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials (2016) (0)
- Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma (2023) (0)
- BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. (2022) (0)
- Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma (2015) (0)
- Drug resistance in melanoma—anything new? (2001) (0)
- Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (0)
- Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA. (2022) (0)
- cTAGE are potential multiple myeloma associated antigens [In: Cancer immunotherapy 2006 meets strategies for immunetherapy p.414] (2007) (0)
- Optimale Systemtherapie beim kutanen Melanom (2017) (0)
- Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2017) (0)
- Novel Predictive Biomarkers in Melanoma Treatment with Ipilimumab (2015) (0)
- LBA40 Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable/metastatic, BRAF V600- or NRAS-mutant melanoma (2022) (0)
- Corrigendum to 'Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data' [Eur J Cancer, 119 (September 2019) Pages 30-34]. (2019) (0)
- 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma (2021) (0)
- P683Cardiovascular adverse events associated with BRAF and MEK inhibitors (2019) (0)
- Navtemadlin (KRT-232) in combination with avelumab for patients with anti-PD-1/L1 treatment-naïve TP53 Merkel cell carcinoma (MCC) (2022) (0)
- Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis (2021) (0)
- ctDNA as a noninvasive monitoring tool in metastatic melanoma. (2019) (0)
- Ex vivo cytokine gene transfer in melanomas by using particle bombardment. (2000) (0)
- Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance (2019) (0)
- PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies (2018) (0)
- Staging bei Patienten mit fortgeschrittenem Stadium eines malignen Melanoms: Wertigkeit der Ganzkörper-MRT im diagnostischen Vorgehen (2006) (0)
- Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (2018) (0)
- Vorwort (2014) (0)
- 572 Photoaging smartphone apps for skin cancer prevention in German adolescents: The Sunface randomized trial (2017) (0)
- XPG D1104 single-nucleotide polymorphisms and the prognosis of melanoma. (2009) (0)
- Editorial Board / Imprint / Innentitel / Inhalt (2016) (0)
- 1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS (2020) (0)
- Vektoren zur gentherapeutischen tumorbehandlung (1999) (0)
- Dermatopathology SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma (2004) (0)
- Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo (2019) (0)
- The vascular phenotype, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma (2010) (0)
- Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib (2021) (0)
- A five‐year observance of changes in the cardiovascular risk profile in 505 HIV‐positive individuals (2012) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Abstract 5647: Intron retention as a novel source of tumor neoantigens associated with response to checkpoint inhibitor therapy (2017) (0)
- Gene-based Vaccination Against Malignant Melanoma (2003) (0)
- Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study (2016) (0)
- Multimodal integration of image, epigenetic and clinical data to predict BRAF mutation status in melanoma. (2023) (0)
- Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI) (2019) (0)
- TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities (2023) (0)
- Merkel Cell Carcinoma Register of the ADO - the first Evaluation (2013) (0)
- Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2023) (0)
- Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI). (2019) (0)
- Abstract CT001: Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial (2018) (0)
- Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways (2019) (0)
- The GERMELATOX DeCOG-trial: Attitude of German melanoma patients towards toxicity during adjuvant interferon treatment—Differences between the patient's and the physician's perspective. (2015) (0)
- Metastatic basal cell carcinoma : Prognosis dependent on anatomic site and spread of disease qq (2014) (0)
- Volume Index 2011 (2011) (0)
- Inside the USCAP Journals (2022) (0)
- [Comment on the contribution by J. Petres et al. Effective lymph node dissection in primary malignant melanoma]. (1996) (0)
- The Influence of HLA and KIR Genes on Malignant Melanoma Development and Progression (2016) (0)
- Is there a role for immune checkpoint blockade in metastatic uveal melanoma? (2015) (0)
- Relevance of autoantibody profiles in the early detection of cancer (2008) (0)
- Dose Seeking Evaluation of a Novel Heterologous Primeboost Immunotherapy in Stage III and IV Metastatic Melanoma Patients (2004) (0)
- Interaktives Expertenforum Melanom: Juni 2016 (2016) (0)
- 7 Evolution of cross-resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma (2018) (0)
- Cutaneous melanoma (0)
- Myeloprotection of amifostine in patients with stage IV malignant melanoma treated with fotemustine chemotherapy: 411 (1997) (0)
- Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions (2022) (0)
- Analysis of BRAF V600E mutation status – concordance of results from circulating tumor DNA and tissue-based testing and impact on prediction of the clinical course in patients undergoing BRAFi therapy (2016) (0)
- COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study (2023) (0)
- Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]. (2021) (0)
- Rare TERT Promoter Mutations Present in Benign and Malignant Cutaneous Vascular Tumors (2021) (0)
- Apoptosis in Melanoma (2006) (0)
- Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials (2016) (0)
- Abstract 3031: PHIP is a therapeutic target for triple negative solid tumors (2017) (0)
- Metastasiertes pigmentiertes epitheloides Melanozytom bei einer 7‐jährigen Patientin (2021) (0)
- Temozolomide (TMZ) in combination with pegylated interferon alfa-2b for stage IV metastatic melanoma: A multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). (2016) (0)
- European Journal of Skin Cancer Editorial (2023) (0)
- Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist (2021) (0)
- Bacteria as Vectors for Gene Therapy of Cancer (2003) (0)
- 814P Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3 (2022) (0)
- New TRP-2-derived T helper epitopes identified in HLA-DRB1*0301 transgenic mice elicit spontaneous T cell responses in HLA-DRB1*03 and HLA-DRB1*04 melanoma patients (2004) (0)
- Deep learning detection of melanoma metastases in lymph nodes (2023) (0)
- Abstract CT197: Phase Ib study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma (2022) (0)
- Skin Cancer Classification Using Convolutional Neural Networks with Integrated Patient Data: A Systematic Review (Preprint) (2020) (0)
- PD-L1 EXPRESSION AND EFFICACY IN PATIENTS TREATED WITH PEMBROLIZUMAB VS IPILIMUMAB FOR ADVANCED MELANOMA IN KEYNOTE-006 (2016) (0)
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. (2023) (0)
- Guideline-Based Context-Sensitive Decision Modeling for Melanoma Patients (2022) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Abstract SY45-04: Development of therapeutic strategies by resolving the tumor ecosystem (2019) (0)
- Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study (2019) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i (2020) (0)
- Vorwort (2011) (0)
- Review Genetic Alterations and Personalized Medicine in Melanoma (2014) (0)
- Management of partial and non‐responding cutaneous squamous cell carcinoma (2021) (0)
- NF1 mutations in conjunctival melanoma (2018) (0)
- Regulatory T Cells in + Foxp 3 + CD 25 Transgenic Mice Despite the Depletion of ret Skin Melanoma Development in Mahnke (2009) (0)
- Efficacy of PD-1 based Immunotherapy after radiological Progress under targeted Therapy in Melanoma (2019) (0)
- Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma (2023) (0)
- 1077P Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE) (2021) (0)
- L5 RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell responses in combination with anti-PD-1 immune checkpoint blocking antibodies (2020) (0)
- Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma (2020) (0)
- Molecular features of response to anti-PD-1 therapy. (2016) (0)
- dictors of Sun Protection Behaviors and Severe Sunburn B & P n International Online Study (2010) (0)
- Statin use and its effect on all-cause mortality of melanoma patients (2017) (0)
- The development of the BRAF inhibitor encorafenib (LGX818) and mitogen-activated protein kinase kinase inhibitor binimetinib (MEK162) in patients with metastatic melanoma (2014) (0)
- Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence (2023) (0)
- Vorwort (2015) (0)
This paper list is powered by the following services:
Other Resources About Dirk Schadendorf
What Schools Are Affiliated With Dirk Schadendorf?
Dirk Schadendorf is affiliated with the following schools:
- Johns Hopkins University
- University of Tübingen
- University of Texas Southwestern Medical Center
- University of Duisburg-Essen
- Saarland University
- Medical University of Graz
- Humboldt University of Berlin
- MD Anderson Cancer Center
- University of Sydney
- University of Oxford
- University of Cologne
- Kiel University
- Aix-Marseille University
- University of Glasgow
- University of Western Australia
- Yale University
- University of Wales